

WO02062135

Publication Title:

SCCE MODIFIED TRANSGENIC MAMMALS AND THEIR USE AS MODELS OF HUMAN DISEASE

Abstract:

Genetic evidence that an imbalance in the activity of serine proteases can cause severe skin disease has recently been presented. The serine protease SCCE is preferentially expressed in cornifying epithelia. Increased expression of SCCE in psoriasis has previously been reported. Increased SCCE expression also in chronic lesions of atopic dermatitis is described herein. Transgenic mice expressing human SCCE in suprabasal epidermal keratinocytes were found to develop pathological skin changes with increased epidermal thickness, hyperkeratosis, dermal inflammation, and severe pruritus. The results strengthen the idea that SCCE may be involved in the pathogenesis of inflammatory skin diseases, and may offer a new therapeutic target.

Data supplied from the esp@cenet database - <http://ep.espacenet.com>

This Patent PDF Generated by Patent Fetcher(TM), a service of Stroke of Color, Inc.

BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 August 2002 (15.08.2002)

PCT

(10) International Publication Number
WO 02/062135 A2

(51) International Patent Classification⁷: **A01K 67/027**,
C12N 9/64, A61K 49/00, G01N 33/50

(21) International Application Number: PCT/IB02/01300

(22) International Filing Date: 8 February 2002 (08.02.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2001 00218 9 February 2001 (09.02.2001) DK
2,332,655 9 February 2001 (09.02.2001) CA

(71) Applicants and

(72) Inventors: **EGELRUD, Torbjörn** [SE/SE]; Generals-
gatan 11, S-903 36 Umeå (SE). **HANSSON, Lennart**
[SE/SE]; Heymans vag 13, S-435 43 Pixbo (SE).

(74) Agent: **PLOUGMANN & VINGTOFT A/S**; Sankt Annæ
Plads 11, P.O. Box 3007, DK-1021 Copenhagen K (DK).

(81) Designated States (*national*): AE, AG, AL, AM, AT (util-
ity model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ (utility model), DE (utility model),
DK (utility model), DM, DZ, EC, EE (utility model), ES,
FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM,
PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model),
SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: SCCE MODIFIED TRANSGENIC MAMMALS AND THEIR USE AS MODELS OF HUMAN DISEASE

(57) Abstract: Genetic evidence that an imbalance in the activity of serine proteases can cause severe skin disease has recently been presented. The serine protease SCCE is preferentially expressed in cornifying epithelia. Increased expression of SCCE in psoriasis has previously been reported. Increased SCCE expression also in chronic lesions of atopic dermatitis is described herein. Transgenic mice expressing human SCCE in suprabasal epidermal keratinocytes were found to develop pathological skin changes with increased epidermal thickness, hyperkeratosis, dermal inflammation, and severe pruritus. The results strengthen the idea that SCCE may be involved in the pathogenesis of inflammatory skin diseases, and may offer a new therapeutic target.

WO 02/062135 A2

SCCE MODIFIED TRANSGENIC MAMMALS AND THEIR USE AS MODELS OF HUMAN DISEASES

FIELD OF INVENTION

5 The present invention relates to transgenic scce mammals and mammalian embryos, their use as models of studying human diseases, to methods of using these models for identifying compounds and compositions effective for the treatment of these diseases, and to the compounds and compositions themselves. In particular, the invention relates to transgenic mammals overexpressing a scce gene in the skin. These model animals display
10 a major change in phenotype characterized by a severe skin disorder and are useful for identifying compounds and compositions for the treatment of various human diseases.

GENERAL BACKGROUND

The skin as an organ is of interest from biological, medical, and cosmetological points of
15 view. There are a large number of skin diseases that are either organ-specific, e.g. psoriasis and eczemas, or are manifestations of general disease, such as general allergic reactions. The fact that there are skin-specific diseases can be considered as a proof of the existence of molecular mechanisms that are unique for the skin. Analogously, studies on skin-specific molecular processes are of importance for the understanding and treatment of
20 skin disorders. It seems reasonable to assume that several of these processes in one way or another are related to the most specialized function of the skin, that is the formation of a physico-chemical barrier between body exterior and interior. The physico-chemical skin barrier is localized in the outermost layer of the skin, the stratum corneum.

25 The stratum corneum is the most specialized structure of the skin. It is the end product of the differentiation process of the epidermis, that is the stratified squamous epithellum that accounts for the outermost portion of the skin. The majority of the cells of the epidermis consist of keratinocytes in various states of differentiation. The lowermost keratinocytes, the basal cells, reside on a basal membrane in contact with the dermis, that is the
30 connective tissue of the skin, and are the only keratinocytes that have dividing capability. A fraction of the basal cells continuously leaves the basal membrane and goes through a differentiation process, which eventually makes the cells become building blocks of the stratum corneum. In this process the keratinocytes go through a number of adaptive changes. There is an increased content of cytoskeleton consisting of epidermis-specific
35 cytokeratins. The intermediate filaments of contiguous cells are joined to a functional unit by an increased number of desmosomes. The most dramatic changes take place during the

- transition from the uppermost living cell layer, the stratum granulosum, to the non-viable stratum corneum in a process usually called keratinization. Covalently cross-linked proteins are deposited close to the inner aspect of the plasma membrane, forming a very resistant cell envelope. Furthermore a lipid-rich substance, originating in a keratinocyte-specific cell organelle, is secreted to the extracellular space and, by forming lipid lamellae, which surround the cells of the stratum corneum, constitutes the permeability barrier to hydrophilic substances. Finally all intracellular structures except the densely packed cytokeratin filaments disappear.
- 10 The cells of the stratum corneum, the corneocytes, are thus non-viable. This means that the regulation of various processes in the stratum corneum must be the result of a "programming" at a state where the keratinocytes are still viable. The turnover of the epidermis, which normally proceeds in about four weeks during which the cells are part of the stratum corneum for about two weeks, is ended by means of cell shedding from the skin surface in the process of desquamation. This process is an example of "programming" of the stratum corneum. A prerequisite for the function of the stratum corneum as a physico-chemical barrier is that its individual cells are held together by mechanically resistant structures, that is desmosomes. The degradation of desmosomes, which is a prerequisite for desquamation, must be regulated so as to give a cell shedding from the skin surface which balances *de novo* production of the stratum corneum without interfering with the barrier functions of the tissue.

Disorders of keratinization

- 25 Under a large number of pathological conditions in the skin of varying severity, there are disturbances in the keratinization process. In psoriasis there is, in addition to a typical chronic inflammation, overproduction of an immature stratum corneum resulting in the typical scaling of this disease. There is a group of inherited skin diseases characterized by a thickened stratum corneum which leads to the formation of "fish scales", the so-called ichthyoses. In several of the ichthyoses there is a decreased rate of desquamation. Although less severe than the ichthyoses, "dry skin" (xeroderma) is also characterized by a stratum corneum from which corneocytes are shed, not as under normal conditions as single cells or as small aggregates of cells, but as large, macroscopically visible scales. This disorder is very common among elderly people and among atopics, that is individuals with a decreased resistance to skin irritants and a disposition to develop a characteristic form of endogenous eczema. In the acne diseases there is a disturbed keratinization in the ducts of the sebaceous glands, which leads to the formation of comedones and plugging. The formation of comedones precedes and is believed to provoke the inflammatory acne lesion.

Proteolytic enzymes are involved in keratinization

There are several stages in the keratinization process and during the turnover of the stratum corneum where proteolytic enzymes seem to play important roles. Certainly the disappearance of all intracellular structures except for the cytokeratin filaments occurring during the transition between viable and cornified epidermal layers must involve proteolysis. The transformation of profilaggrin to filaggrin, a protein that is believed to function in the special type of aggregation of cytokeratin filaments during keratinization, may be catalyzed by a specific proteinase. In the stratum corneum filaggrin is further degraded to low-molecular weight components which are probably important as "natural moisturizers". Furthermore there are proteolytic modifications of cytokeratin polypeptides during the keratinization process. Finally, proteolytic events are likely to play crucial roles in the degradation of intercellular cohesive structures in the stratum corneum in processes eventually leading to desquamation.

15

Stratum corneum cell cohesion and desquamation. The role of desmosomes

Intercellular cohesion in the stratum corneum as well as in the viable parts of the epidermis is mediated to a significant extent by desmosomes. A desmosome consists of two symmetrical halves, each of which is formed by two contiguous cells. Each desmosomal half has one intracellular part linked to the cytokeratin filaments and one part made up by glycoproteins anchored intracellularly and with transmembranal and extracellular parts. The extracellular parts of these proteins, the desmogleins, are adhesion molecules, and through their interaction with each other in the extracellular space a cohesive structure is formed. The degradation of desmosomes seems to follow somewhat different routes in the stratum corneum of palms and soles as compared to non-palmo-plantar stratum corneum. In the latter tissue around 85% of the desmosomes disappear soon after the cells have become fully cornified. The remaining desmosomes, which are preferentially located at the villous edges of the extremely flattened cells, apparently remain intact up to the level where desquamation takes place. In palmo-plantar stratum corneum the corneocytes are much less flattened, and there is no extensive degradation of desmosomes in deeper layers of the tissue. In both tissues desquamation is associated with desmosomal degradation. In ichthyotic skin as well as in "dry skin", the number of desmosomes in the superficial layers of the stratum corneum has been shown to be increased.

Many of the tissue-specific molecular mechanisms of the skin are associated with the formation and turnover of the barrier-forming outermost layer of the epidermis, the stratum corneum, consisting of cornified epithelial cells surrounded by highly organized

- lipids. The stratum corneum is continuously being formed in the process of epidermal differentiation. In the efforts to understand the mechanisms by which a constant thickness of the stratum corneum is maintained via a continuous desquamation of surface cells, two human serine proteases, stratum corneum chymotryptic enzyme (SCCE) and stratum corneum tryptic enzyme (SCTE) have been identified (Hansson et al. 1994 and Brattsand et al. 1999). The cloning and expression of SCCE is described in WO95/00651, which hereby is incorporated by reference. Both enzymes belong to the kallikrein group of serine proteases, the genes of which are localized to a short stretch at chromosome 19q13.3-19q13.4 (Diamandis et al. 2000). SCCE is synonymous with human kallikrein 7 (KLK7). It should be noted however, that the numbering of kallikreins is not consistent between species. The expression of SCCE and SCTE seems to be restricted to squamous epithelia undergoing cornification and in which there is a need for desquamation (Ekholm et al. 2000).
- Common inflammatory skin diseases may result in severe handicap by causing reduced function, stigmatization, and almost unbearable sensory symptoms. A dominating symptom of many of these diseases is itch, which in many instances may be extremely troublesome, causing severe disturbances in many aspects of every day life and sleeping patterns of sufferers. In atopic dermatitis, affecting more than 10% of children at some point of their childhood, pruritus is a major diagnostic criterion and always present in active disease. It has even been stated that "atopic dermatitis is an itch that when scratched erupts", and that "pruritus must be considered a quintessential feature of atopic dermatitis" (Beltrani, 1999). The mechanisms of itch are poorly understood, and available treatments are often unsatisfactory. This may be due, at least in part, to lack of satisfactory animal models (Greaves and Wall, 1996).

- In inflammatory skin diseases such as psoriasis and atopic dermatitis evidence in favor of a central role for the immune system in pathogenesis is overwhelming. It seems likely that the development of the various disease-specific skin lesions and signs is the result of interactions at the cellular and molecular level between the immune system and skin-derived structures and molecules. In most studies aimed at understanding these interactions focus has been on cytokines, growth factors, and adhesion molecules. Although many of these components are produced by skin cells, they are not unique for the skin, but are more or less generally present in cells and tissues throughout the body. This fact may cause problems in e.g. development of skin-specific therapies. The situation would be different if one could find a truly skin-specific structure or molecule with a central role in the pathophysiology of inflammatory skin diseases. The present invention presents new evidence that the serine protease stratum corneum chymotryptic enzyme (SCCE) may belong to this category of skin-specific molecules.

SUMMARY OF THE INVENTION

The present invention relates to results from studies aimed at elucidation of the possible involvement of one of these proteases, SCCE, in skin pathology. The human and murine
5 scce-genes were characterized, and transgenic animals overexpressing human scce mRNA produced. The only gross phenotypic changes observed in these animals were found in the skin, which showed histological changes with several similarities to those seen in inflammatory skin diseases such as in the chronic stages of atopic dermatitis in humans. In addition, the transgenic animals showed signs of severe itch. Evidence of over-expression
10 of SCCE in chronic lesions of atopic dermatitis in humans was also found corresponding to what has recently been shown in psoriasis (Ekholm et al. 1999). Taken together, the results give support for the idea that SCCE and related enzymes may be involved in the pathophysiology of itchy inflammatory skin diseases, and thus that SCCE may be a potential target for organ-specific treatment strategies. The transgenic animals of the
15 invention may provide a new model for further studies of itch mechanisms and the testing of potential compounds and compositions for relieve of various skin diseases where itch is a component.

The human SCCE gene was isolated from a human leukocyte genomic library cat. no. HL
20 1111 j lot # 3511 (Clontech, CA) by using cDNA probes derived from the human scce cDNA. Overlapping clones were isolated and the entire structural gene was sequenced by automated DNA sequencing and analyzed by ABI377 (Applied Biosystems, Foster City, CA, USA). The entire sequence can be found using Gene Bank accession no AF 332583.

25 Table 1 Human SCCE [org=Homo sapiens] Homo sapiens stratum corneum chymotryptic enzyme gene (SEQ ID NO:3).

TACCACATTTTCTTAATCCAGTCTATCACTGATGGACATTTAGGTTGATTCCCTGTGTTTGCTGTTGT
CAATAGTTCTACAATGAACGTACGTGTCCATGTGTCTTTAAACAGAATGATTTATATTCCTTTGGGTA
30 CACACACTGGGGCTTATGAGAGGGTGGAGAGTGGGAGGAAGGAGAGGATCAGAAAAAATAACTA
ATGGGTACTAGGCTTAATACCTGGGTGATTAAATAATCTGTATAACAAACCCCATGGCGCACGTTT
ACCTACGCAACAAACCTGCACATCCTGCACATGTACCCCGAACTGAAAAGTTAAAAAAGAAAAAT
AAATATTTGCTTATAAATTAATAAATGAAGCCCTCAAAAATGTTCTATTAGATAATGTTAAGTACAGA
CATTTTGTATATAAATACATAATATACAAAGAAATCTATGTATAACATGATTAATGACCATAAGAA
35 CATAGATCCTAAACATGGCAAATATTAGTGGGGTGGGGTTAGGGAAAGCGTTGTTTTAACTTACA
CCTCTCTGTAGAGTTGGGAATGGGTTCAGGCGTAATTACAGGCACGACTGGGATCAGCTTGGACA
AGTTCCCCCAGGCGGGCCAGAATTAGGATGTAGGGTCTAGGCCACCCCTGAGAGGGGGTGAGGG
CAAGAAAATGGCCCCAGAAGCCGGGCGCAGTGGCTCACGCCTGTAATCCAGCACTTTGCGGGGC

CGAGGCGGGCACATCATGAGGTCAGGAGATCGAGACCATTCTGGCCAACATAGTGAAACCCGGTC
TCTACTAAAAATACAAAAATTATCTGGGAGTGGTGGTGCCTGTAATCCCAGGTACTCGGGAG
GCTGAGGCAGGAGAATCACTTGAACCTGGGAGGCGGAGCTGGCAGTGAGCCGAGATCGCGCCAC
CGCACTCCAGCCTGGCGATAGAGAGAGACTCCATCCAAAAAAGAAAGGAAGGGAGGGAGGGA
5 GGAGGGAAGAAAGAAAGAAACCGCCCCAGAGAAGGACCCGAGCCAGAGCCTATTCTCTGAGCTC
AGCGACTGCTTGAATCCCGCTCCTGCCCTCAGACCCAGCGCACCGGGTCCCTCCCCGAGAGCA
GCCAGGAGGGACTGTGGGACCAGAATGTGCGGGGGCGCAGGAGCTGGGCACCGCCCGTCCTTCG
GAGGGAGGGTGGAGAGAGAGTGCAGTGGTGCCAATTGCTCTCGCTGCGTCAGGGTTCCAGATAAC
CAGAACCGCAAATGCAGGCGGGGGTGTCCAGAGTCGGCTCCGCCTGCACCCAGGGCGCTGGG
10 GCCGGGCATGGGGCGGGGGGTGATATAAGAGGACGGCCAGCAGAGGGCTGAAGATTTTGGAGC
CCAGCTGTGTGCCAGCCCAAGTCGGAACCTTGGATCACATCAGATCCTCTCGAGGTGAGAAGAGGC
TTCATCAAGGGTGCACCTGTAGGGGAGGGGGTGTGCTGGCTCCAAGCCTGACTCTGCTCTCGAG
AGGTAGGGGCTGCAGCCTAGACTCCCGGTCTGAGCAGTGAGGGCCTGGAAGTCTGCAATTTGGG
GCCTTTTAGGGAAAAACGAACTACAGAGTCAGAAATTTGGGTTCCACAGGGAAGGGCAAGATCGG
15 AGCCTAGATTCTGGGTCTCTAGGGATCTGAAGAACAGGAATTTGGGTCTGAGGGAGGAGGGGC
TGGGGTTCTGGACTCCTGGGTCTGAGGGAGGAGGGCCTGGGGCCTGGACTCCTGGGTCTGAGG
GAGGAGGGGCTGGGGGTCTCGACTCCTGGGTCTGAGGGAGGAGGGGCTGGGGCCTGGACTCC
TGGGTCTGAGGGAGGAGGGGCTGGGACCTGGACTCCTAGGTCTGAGGGAGGAGGAGCTGGGGC
CTGGACTCCTGGGTCTGAGGGAGGAGGGGCTGGGGCCTGGACTCCTGGGTCTGAGGGAGGATGG
20 GCTGAGGCCTAGACTCCTGGGTCTGAGGGAGGAGGGGCTGGGGCCTGGACTCCTGGGTCTGAGG
GAGGAGGGGCTGGAGCCTGGACTCCTGGGCCTGAGGGAGGAGGGACTGAGACCTGGACTCCTAG
GTCTGAGGGAGGAGGGACTGGGACCTGGACTCCTGGGTCTGAGGGAGGAGGAGCTGGGGCCT
GGACTCCTGGGTCTGAGGGAGGCGGGGCTGGGGCCTGGACTCCTGGGTCTGAGGGAGGAGGG
GTTGGGGCCTGGACTCCTGAGCCTGAGGGAGGAGGGACTTGGACCTGGACTCCTAGGTCTGAGG
25 GAGGAGGAGCTGGGGCCTGGACTCCTAGGTCTGAGGGAGGAGGGGCTGGGGCCTGGACTCC
TGGGTCTGAGGGAGGAAGGTGCTAGGGTCTGGACTCTTGGGTATGAGGGAGGAGGAGGTTAGGG
GTCTGGACTTCTGAGTGTAAAGGAAGGAGAGGCCAGAGAAAGGAATTTCTGGGTCTGAGGGAGGAG
GGGCTGGGGTTCTGGACCCCTAGGTCTGAGGGAGGAGGGGCTGGGGCCTGGACTCCTGGGTCTG
TGGGGGAGGGGCTGGGGCCTGGACCCCTGGGTCTGAGTGGGGAGGGGCTGGGCCTGAATGCT
30 TTCTCCTTCTCAGCTCCAGCAGGAGAGGCCCTTCTCGCCTGGCAGCCCTGAGCGGCTCAGCAG
GGCACCATGGCAAGATCCCTTCTCCTGCCCTGCAGATCCTACTGCTATCCTTAGCCTTGAAAAC
GCAGGAGAAGAAGGTGAAAGCTGGACTGGGAAGTCTGACCTCACCTCAGGGCCCCCACTGACCC
CTCCAAGGAGTCCCTGAGTCAGAACCTTCCCTCCTCAAACAGCTTCCATCCTGGGAGGACCAGAC
TGTCGGCTGAAGCCCCGCTCTTCTGCTTCTGCTGACTCAGGGGGTCTCTGTCCCCTCCAGGCCC
35 TGCCTCCTGTGCTCAGGGTCTCTCTGTGGTTCCCAGATGAGATGCGCCTCCTGGGTTTCTGAGTG
GGCTCCTTCTGTCTGTCTCTATCCCTATCTTGTCTTCTCTGTATTTCTCCACACATTTTCATCTGTC
TCTGTCCATCTCTGACTCTGGGAATCCCTGAGGTGCAGCCTCAGCCTTCCCCTAATGCTAGCTACCC
ACATGCTCCTCCATGTCTCCATCCAGCCAGGGTGACAAGATTATTGATGGCGCCCCATGTGCAAG
AGGCTCCCACCCATGGCAGGTGGCCCTGCTCAGTGGCAATCAGCTCCACTGCGGAGGGCGTCTGG

TCAATGAGCGCTGGGTGCTCACTGCCGCCCACTGCAAGATGAAGTAGGTGCCACCCAAGTCTCTG
CTGGAGGTGCGCCAGCATCTCCAGCTCGCTATGGGGGTGGAAGGGCAGTCTTTCTGTGCCTACGG
CTCTATTCTCCTCTCTCTGGGTCTCTGTCCCCCTCTCTCTGGGCCTCTGTACCCCCTCTCCCTGGGG
CTCTGTCCCCCTCTCTCCCTGGCTCTCTGTCTCCCTCTCTCTGGGTCTCTGTCCCCCTCTCTCTGGA
5 TCTCTGTCCCCCTCTCTCTGTGTCTCTGTCCCCCAATTCTCTCTAGGTCTCTGTTCCCCCTCCTCTCTC
TCTGGGTCTCTGTCCCTCTCTCTCTGGTCTCTGTCCCCCTCTCTCTCTGGATCTCTGTCCCCCTCTCC
CTGGGCCTCTGTACCCCCTCTCCCTGGGGCTCTGTCCCCCTCTCTGGGTCTCTGTCTGCCTTTCTC
TCTGGATCTCTGTTCCCCCTCTGTGTCTCTGTCCCCCTCTCTCTCTGGGTCTCTGTTCCCCCTCCTCTC
TTTCTGGGTCTCTGTCCCTCTCTCTCTGGGTCTCTGTCCCCCTCTCTCTCTGGGTCTCTGTTCCCCCTC
10 CTCTCTCTCTGGTCTCTGTCCCTCTCTCTCTGGGTCTCTGTACCCTCTCTCTCTGGGTCTCTGTAC
CCTCTCTCTCTGGTCTCTGTTCCCCCTCCTCTCTCTGTGGGTCTCTGTCCCTCTCTCTCTGGGTCTCT
GTTCCCCCTCTCTCTCTGGTCTCTGTTCCCCCTCCTCTCTCTCCGGATCTCTGTCCCCCTCTCCCTGG
GGCTCTGTCCCCCTCTCTCCCTGGCTCTCTGTCTTCTCTCTCTGGGGCTCTGTCCCCCTCTCTCTC
TGGTCTCTGTTCCCCCTCTCTCTGGGTCTCTGTCCCTCTCTCTCTGGGTCTCTGTCCCTCTCTCTCTG
15 GATCTCTGTCCCCCTCTCCCTGGGCCTCTGTACCCCCTCTCCCTGGGGCTCTGTCCCCCTCTCTCTG
GGTCTCTGTCTGCCTTTCTCTCTGGATCTCTGTTCCCCCTCTGTGTCTCTGTCCCCCTCTCTCTCTGG
GTCTCTGTTCCCCCTCCTCTCTTTCTGGGTCTCTGTCCCTCTCTCTCTGGGTCTCTGTCCCCCTCTCT
CTCTGGTCTCTGTTCCCCCTCCTCTCTCTCTGGTCTCTGTCCCTCTCTCTCTGGGTCTCTGTACCCT
CTCTCTCTGGGTCTCTGTACCCTCTCTCTCTGGTCTCTGTTCCCCCTCCTCTCTCTGTGGGTCTCT
20 GTCCCTCTCTCTCTGGGTCTCTGTTCCCTCTCTCTCTGGTCTCTGTTCCCCCTCCTCTCTCTCCGGA
TCTCTGTCCCCCTCTCCCTGGGGCTCTGTCCCCCTCTCTCCCTGGCTCTCTGTCTTCTCTCTCTGG
GGCTCTGTCCCCCTCTCTCTCTGGTCTCTGTTCCCTCTCTCTGGGTCTCTGTCCCTCTCTCTCTGG
GTCTCTGTCCCTCTCTCTCTGGATCTCTGTCCCCCTCTCTCTCTGGGTCTCTGTTCCCTCTCTCTGG
GTCTCTGTCCCTCTCCTCTCTCTGTGTCTCTCTCCCCCTCCTCTCTCTGTGTCTCTGTCCCCCTCC
25 TATCTCTGTGTCTCTCTCCCCCTCCTCTCTCTGGGTCTCTGTCCCCCTCTCTGGGTCTCTGTCTC
CCTCTCTCTGGGGCTCTGTCCCCCTCTCTCTCTGGATCTCTGTTCCCTCTCTCTGGGTCTCTGTCT
CCCCCTCCTCTCTCTGTGTCTCTGTCCCCCTCCTCTCTCTGGGTCTCTGTCCCCACCCCGTCCCCCA
GGTCTTTGCACACCCTCTCTGTACAGTGTCTTCTGAATCTGTGAATGTCACTCCTCGCAGTGAG
TACACCGTGACCTGGGCAGTGATACGCTGGGCGACAGGAGAGCTCAGAGGATCAAGGCCCTCGAA
30 GTCATTCCGCCACCCCGGCTACTCCACACAGACCCATGTTAATGACCTCATGCTCGTGAAGCTCAAT
AGCCAGGCCAGGCTGTCATCCATGGTGAAGAAAGTCAGGCTGCCCTCCCGCTGCGAACCCCTGG
AACCACCTGTACTGTCTCCGGCTGGGGCACTACCACGAGCCCAGATGGTAGGTGGCCTCAGTGAC
CCAGGAGTGACAGGCCCCAGCCCTCCTCCCTCAGACCCAGGAGTCCAGGCCCCCAGCCCTCCTCC
CTCAGACCCAGGAGTCCAGGCCTCAGCCCCTCCTCCCTCAGACCCAGGAGTCCAGGCCCCCAGCC
35 CCTCCTCCCTCAGACCCGCGAGTCCAGACCCAGCCCCTCCTCCCTCAGACCCAGCAGTCTCTGGGG
CCCAGACCCTCCTCCCTCGGAACCAGGAGCCTGAACAACAGCCCTTCTGGTCTCGCCCCCATCCT
CTCTGACTGACAGCTCTCCCTGCTCCTCCCTGCAGTGACCTTTCCCTCTGACCTCATGTGCGTGGAT
GTCAAGCTCATCTCCCCCAGGACTGCACGAAGGTTTACAAGGACTTACTGGAAAATTCCATGCTG
TGCGCTGGCATCCCCGACTCCAAGAAAAACGCCTGCAATGTGAGACCCTCCCCCCCCAATTCCTCCC

CAGTCCTGGGTACCCTGTCTGCATGCCCCAGGGACAGAGCTTGACCCAAGTGACTGGGTACCAAG
CCCGGCCTTGCCCTCCCCCAGGCCTGGCCTCCTCAGCTTTTTCCACCTCATTCTCTGCCTAGGTCA
GGGGTGGGAGTTTACTTAGGGGCCGATGTGGCCCTGGGGATGGGACAGAGAGTTTAATAGGGGT
GAGAAAGTGGGGGTGGGACCAGGGAAGGAGACTGAGGTGCTGGCCTCAGGCCCAAACCTAAGG
5 GGGCACCAAAAACCTCAGTGATTGAGATAAATCATAATGCAATATTTAAAAATAAAAATAAAAATC
ATGCAGAAAGTCCATGATGGACAAAATGTCACATTTTAAATAAAGAGCAGGTGGATCTTACTGAATTT
TCCCTTGCCGTAAGTACTAGCGTGGCTCAGCACAGCGCTGACTGGCACTGTCTTCATTTAAATGT
GGATACCATGCCCATCATGCAGTTTTATGTATTACATTTGATTTGTTAAGTACTGCATTGAAGTATT
GTGTATTGCAGTTACTGAGATTTGTGCCTGAAGCTGATGACTCACTCACCTGACCCTGGCCCTGG
10 TCCCGGGGAAAACACTCTTTCTCTCCACCTCCTCTCTGTTCCCTCTTTCTGGCCTTTTGTATCCCCT
CTGTTTCTGAACAGTCTTCCACATCTCTCTTTGTGACATAATTTCAATTCATTCTTTTCTCTTTGTT
TTTTCTCTGTGTTGAGCTAGCTTGCTCTCCCTCCCTGTTCTCTCTCCATGCCCTCCTCTCTGCTCTC
TGTCTTCTCCCTCTTTCTCTTGCTTCTCTCTCTCTCCTCCCTCCCTCTCTCCTCTCCCTGCCCCCT
GCTCTCTTTTTTCTCTCTCTGTCTCCTCTCTGGCCCTCTCCTCTTTCTCTCTCTCCCCACTTC
15 TCTGTCTCTTTCATCTCTCTCCCTCATCTCTCCTTGCCCCCTCCTTTTTACTGTCTCTCTTTTCTCT
TTCTTCTATCTCTCTCCTCTCCCCGCCGCTCCCCCATCTCTGTCTTTCTTTCTCTCTTTATTCTCCT
CCTCTCTTCCAGTCTCTCTCTCCTCTCCCCACCCCCACCCCATCTCTCTCCCCACACCTTCCCCCCT
TTCTCTTTGTCTCTCTCTTCTACCTCTTTCTTCTCCACCCCCATCTCTCTCTCTTCTCTTCCCACAC
CCTCCCCATCTCCCTCATCTCTTTGTCTGTCTCTTCTCCCTCCTTCTTTTCCACCCCCATCTCTCTG
20 TCTCTCTCTCTCCCCATACCCTTTCCCTCTTCTCATCTCTCTTTGTCTCTCTCTCCTTTCCCTCTTTC
TTCTCCACCTCCAATCTCTCTGTCTCTCCACACCCATCCTCCTTGCTCACATCTGCACCTTCAGCTG
TCAGGGGATGTGGGATGGTGAGTGTTAGGGATAGAGGAGATGGGAGAGAGATGACTGTCCTAGA
GAATAGGGTGTTCCCTTCTCCCTGGTGAGGGCCAGTTTCATGAATGTGCAAGCTCTGCACGGAC
ACAGAGCCCCCACTCAGAAGGGTCTCAAACCTAGTCTAATGCATTCTGCTGTTGTCTTGAAATTC
25 TCAATAATTTTGAACAAAGGGCCCTGCATTTTCGTTTTGCACCAAGTCTGTAAATTATGTAAGTGG
TCTTACCCTGGTCTCCGAGACCATCGTGTCCTTCTCCTGCGCCACAGGGCAGCATCCACCCC
TTGGAGATGATGTTCTTCTCCCACTAGCTTGGAGCAGGGTCCTTAACATTGGAAAATAAAGAGTG
CTCTGATCCTGGAAGCCCCACCCCTTCTCTGCAATTGGTCTCATTGGCCAAGGGTCAAACAGTGT
CTTCAAAGGACCTAGTGTGTCCCTAGCACTAGCTCTCCCATAGTCCCCAGAGACAATGAGTCTCTT
30 CTCATTGGCTATGGTGGAAGTCCATAATCTGCAAGACAAAGACCGATAACTGAGGAATGTATGAGA
ATGAGTTGGGCTTTGATCTGAAGCCAAAGTTAATCTCCGGCTCTATTCCCTCTAGGGTGACTCAGG
GGGACCGTTGGTGTGCAGAGGTACCCTGCAAGGTCTGGTGTCTGGGGAACCTTCCCTTGCGGCC
AACCCAATGACCCAGGAGTCTACACTCAAGTGTGCAAGTTCACCAAGTGGATAAATGACACCATGA
AAAAGCATCGCTAACGCCCACTGAGTTAATTAAGTGTGTGCTTCCAACAGAAAATGCACAGGAGT
35 GAGGACGCCGATGACCTATGAAGTCAAATTTGACTTTACCTTTCTCAAAGATATATTTAAACCTCA
TGCCCTGTTGATAAACCAATCAAATTTGGTAAAGACCTAAACCAAAACAAATAAAGAAACACAAAAC
CCTCAGTGCTGGAGAAGAGTCAGTGAGACCAGCACTCTCAAACACTGGAAGTGGACGTTTGTACA
GTCTTTACGGAAGACACTTGGTCAACGTACACCGAGACCCTTATTCACCACCTTTGACCCAGTAACT
CTAATCTTAGGAAGAACCTACTGAAACAAAAAAAATCCAAAATGTAGAACAAGACTTGAATTTACCA

TGATATTATTTATCACAGAAATGAAGTGAAACCATCAAACATGTTCCAAAAGTACCAGATGGCTTAA
 ATAATAGTCTGGCTTGGCACAACGATGTTTTTTTCTTTGAGACAGAGTCTCTGTTGCTTGGGCTGC
 AATGCAGTGATGCAATCTTGGCTCACTGCAACCTCCGCCTCCTGGGTTCAAGTGATTCTCGTGCTTC
 AGCCTCCCAAGTACCTGGGACTACAGGTGTGCACCACCACACCAGGCTAATTTTTTGTGTATTTTAA
 5 CTAGAGACAGGGTTTCACCATGTTGGCCAGCGTGGTCTTGAACGCCTGACCTCAGATGATCCACCC
 ACCTTGGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCACGGCCAGCCACAATGATATTA
 CAAACCTATTAATAAATGATACTTAGACAGAATTGTCAGTATTATTCAAGAACATTTAGGCTATAGGAT
 GTTAAATGACAAAAGGAAGGACAAAAATATATATGTATGTGACCCTACCCATAAAAAATGAAATATT
 CACAGAATCAGATCTGAAAACACATGTCCAGACTGCATACTGGGGTCGTCATGAGGTGTCTCCTT
 10 CCTTCTGTGTACTTTTCTTGAATGTGCACTTTTATAACATGAAAAATAAAGGTGGGGAAAAAAGTC
 TGAAGATCTAAGATTGGAGAGAGGTGACCTTTCAGGAAGGGGAGACTAGAAAGAAATATGTGCCTG
 GTTTTGAGCCCTGGTCTGCCGGCCCTGTTCCAGGGCATATTTCCATTTCCCAGATCTCAGTTTTTC
 CTGTCTGTAAATGGGAGAGAGAGGAAAGGATGGAGAGAGGAAGAAGGAAGGGAGGAGGGAGG
 AGAGAACAGGCCAACTTCATCAGCGTGGGAAGGGGTGTGAAAGTGTCTGAGCATCTCACGAGT
 15 GACAAGTGAGGAGGGAGGCTGGCGGTTTTTCAGAGGGATTGGGATGACAGTAGACAGGACACAGG
 GGTCCACAGGGGTCTGCCAGAAGTAAGCAAACAGTGCCGGAGGAAGATGGTGGCACCTGCTCCC
 CAAGAAGGGAGGGAAAGGAACCTCGGGAAGCGGGTAGGATGAGGGAGGAGTCCTCTGTGACTCA
 GAGCCTGGCCACAGCCCCAGCCATCTAACATCAAAGATCCTCTGTGTGGTCACACCTCAGACGCTG
 CTGACCGAGGAGCCACTCCAGCCCAGGACACGCCCTCTACCTGTTCTTCTGTTTTCTCCAGAA
 20 ATTC

To isolate the murine *scce* gene cDNA probes derived from the murine *scce* cDNA (Bäckman
 et al. 1999) were used to screen and isolate clones from a 129SVJ Lambda Fix II genomic
 library cat. no. 946306 (Stratagene, La Jolla, CA). The entire gene sequence was
 25 determined and analyzed as described above. The entire sequence can be found using
 Gene Bank accession no, AF 339930 which is hereby incorporated by reference and is not
 shown here.

The amino acid sequences (as deduced from cDNA) of human and murine SCCE show
 30 around 80% similarity (Hansson et al. 1994 and Bäckman et al. 1999).

The genomic organization of the human and murine *scce* structural genes are
 schematically shown in Figure 1. The most apparent difference between the structural
 genes from the two species is that the introns are longer in the human *scce* gene. As seen
 35 in Figure 1 the *scce* genes from man and mouse both contain six exons, here indicated as
 black boxes, and have the translational start located in exon 2, and the stop codon in exon
 6. Overall the organization of the exon-intron structures of the two genes is similar but due
 to shorter introns, the murine gene is smaller, approximately 4kb as compared to 8 kb. In
 the human gene, the translation initiation site is found 60 nucleotides downstream the 5'-

end of exon 2, and a potential TATA-box approximately 35 bp upstream of exon 1. Similarly, the murine initiation codon is positioned within the second exon, 39 nucleotides downstream of the intron-exon junction.

- 5 To generate transgenic mice with a modified regulation of expression compared to the endogenous *scce*, recombinant human *scce* gene under control of the *SV40 early* enhancer and promoter element was constructed as described in example 2. Three founders shown to be transgenic for *SV40e-hscce* integrated at a single site were obtained and lines were established by further breeding in C57BL/6JxCBA mice. As expected, initial characterization
- 10 of the three lines revealed very large differences in levels of recombinant *scce* expression (see below). In line #1010, which has the highest *hscce* transcript levels, skin abnormalities were apparent, whereas in the two other lines no skin changes or other gross phenotypic deviations could be observed. For further detailed comparative studies of the #1010 transgenics one of the lines with apparently normal phenotype (#107) and non-
- 15 transgenic littermates were included as controls.

- The importance of the transcriptional regulation of the recombinant *scce* gene was demonstrated by the results achieved from other variants of transgenic mouse models. In these experiments different regulatory elements were inserted upstream of a genomic
- 20 fragment comprising the human *scce* structural gene. For example, the mouse/human keratin 14 promoter (Vassar et al.) was utilized with the idea to target the expression of recombinant *scce* to more basal cell layers than is the normal distribution for endogenous SCCE. Also, a long genomic fragment containing the native human *scce* upstream regulatory sequence including the promoter was tested and evaluated. In these
- 25 experiments the resulting transgenic mice neither showed any signs of altered neither skin morphology nor signs of itch. The detailed construct for recombinant *scce* expression comprising the *sv40 early* enhancer and promoter elements resulted in a surprisingly restricted distribution of expression and a transgenic mouse having very interesting changes in skin biology and clear signs of itch. This phenotype and expression pattern
- 30 were surprising since the *sv40 early* regulatory sequences normally mediates high level transcription in proliferative cells whereas here the strongest expression in differentiated keratinocytes was observed.

- To the knowledge of the present inventors, this is the first report of a mouse model for
- 35 itchy inflammatory skin diseases produced by genetic manipulation of an enzyme, which may be skin specific. The *SV40-scce* transgenic mice are likely to give new insights into the pathophysiology of itchy human skin diseases and provide a new animal model for development of treatments directed at an organ-specific target. At the RNA-level expression of SCCE can be detected in several organs, although not at levels comparable

to skin (Hansson et al. 1994 and Brattsand et al. 1999). In non-malignant tissues SCCE protein has so far been found only in high suprabasal cells in squamous epithelia undergoing cornification and with a need for desquamation (Ekholm et al. 2000 and Ekholm et al 1998). The present inventors show here that over-expression of SCCE in mice
5 at a site close to where it is normally expressed leads to a condition which to some extent simulates common, often debilitating human skin diseases such as atopic dermatitis and psoriasis.

In SV40-scce transgenic mice with phenotypic skin changes expression of transgenic SCCE,
10 RNA as well as protein, was found also in other organs, especially small and large intestine, and lungs. The fact that no pathological changes were seen in these organs may be explained either by a resistance or unresponsiveness to effects mediated by SCCE, or by a lack of SCCE-activating enzymes in unaffected organs. SCCE, human as well as murine, is produced as an inactive precursor, which is converted to active protease by
15 tryptic cleavage at a conserved site (Hansson et al. 1994 and Bäckmann et al. 1999). The enzyme responsible for SCCE-activation in the epidermis has not yet been identified.

The SV40-scce transgenic mice had a somewhat unexpected expression pattern of SCCE in the skin. Since the transgene construct contained the SV40 promoter it was expected to
20 find the highest expression at sites with proliferating keratinocytes, i.e. in the basal layer of the epidermis and in hair follicles. On the contrary, no evidence of SCCE-expression was found in basal cells. Instead, as found by immunohistochemistry, there was expression in suprabasal cells, the intensity of which continuously increased with distance from the basal layer. This pattern is similar to that seen in psoriasis (Ekholm et al. 1999) lesions and
25 chronic lesions in atopic dermatitis in humans. A possible explanation may be that the human scce-gene contains internal regulatory elements that suppress its expression in undifferentiated keratinocytes in the epidermis.

The mechanisms by which SCCE can cause a thickened epidermis with hyperkeratosis, a
30 dermal inflammatory infiltrate, and itch remain to be elucidated. According to the current view the SCCE precursor is synthesized in high suprabasal epidermal keratinocytes and stored in lipid rich lamellar bodies. In the process in which a terminally differentiated keratinocyte is transformed from a viable cell to a corneocyte, i. e. a building block of the cornified surface layer of the epidermis - the stratum corneum - the contents of the
35 lamellar bodies, including SCCE-precursor, are secreted to the extracellular space, where conversion of pro-SCCE to active protease is taking place (Sondell et al. 1995). One possibility is that SCCE, which has been activated as postulated, diffuses through the epidermis to the superficial parts of the dermis, thereby inducing epidermal thickening as well as dermal inflammation and activation of itch-mediating nerve endings. In previous

studies on proteases as potential mediators of itch the enzymes were injected intradermally in human volunteers. Injection of trypsin and mast cell chymase caused itch by a mechanism believed to involve release by mast cells of histamine, whereas the itch caused by intradermally injected kallikrein appeared to be mediated by a mechanism not involving histamine (Hägermark et al. 1972 and Hägermark (1974). Treatment with an antihistaminic drug appeared not to relieve the itch seen in SV40-scce transgenic mice (A. Ny and T.Egelrud, unpublished observation). The fact that SCCE detected by immunohistochemistry in skin of SV40-scce transgenic mice was confined to superficial parts of the epidermis suggests that the dermal inflammation and the pruritus observed in these mice were not direct effects of active SCCE. In addition, signs of itch were not seen before the age of around 5 weeks, whereas overexpression of SCCE was found also in younger animals. An alternative explanation to the changes and signs caused by overexpression of SCCE in the epidermis could be that an increased proteolytic activity in the transition zone between viable epidermal layers and the stratum corneum may lead to release of mediators, which diffuse to other parts of the skin where they cause epidermal changes, dermal inflammation, and pruritus. A third possibility is that the epidermal hyperkeratosis and acanthosis, dermal inflammation and pruritus are results of adaptive responses to a deterioration of the barrier function of the stratum corneum caused by increased proteolytic degradation of structures responsible for intercellular cell cohesion in the cornified layer. The proliferative response of the epidermis could be a result either of a direct effects of the released mediators on keratinocytes or an effect which is secondary to the dermal inflammation.

Recently a direct association between a defective epidermal barrier function and aberrant proteolysis in an inherited human condition with severe skin disease was described. Strong evidence was presented that the disease-causing mutations in Netherton's syndrome are localized to a gene coding for a precursor of serine protease inhibitors (Chavanas et al. 2000). These results, together with the present results, suggest that increased activity of serine proteases in the skin may indeed play a significant role in skin pathophysiology. They also provide incentives for further exploring of possible new therapeutic principles for skin diseases.

DETAILED DISCLOSURE OF THE INVENTION

The present invention relates to a non human transgenic mammal or mammalian embryo having integrated within its genome a heterologous nucleotide sequence comprising at least a significant part of a nucleotide sequence coding for a stratum corneum chymotryptic enzyme (SCCE) or a variant thereof operably linked to a promoter that drives expression of the heterologous scce or a variant thereof in skin.

By the term "heterologous" is referred to a DNA sequence inserted within or connected to another DNA sequence which codes for polypeptides not coded for in nature by the DNA sequence to which it is joined. Allelic variations or naturally occurring mutational events do
 5 not give rise to a heterologous DNA sequence as defined herein.

Preferably, the present invention relates to a transgenic mammal or mammalian embryo having integrated within its genome a heterologous nucleotide sequence comprising at least a significant part of a nucleotide sequence coding for a stratum corneum
 10 chymotryptic enzyme (SCCE) or a variant thereof operably linked to a promoter that drives expression of scce in epidermis.

By the term "a human stratum corneum chymotryptic enzyme (SCCE)" is meant a serine protease having the amino acid sequence SEQ ID NO:2 described in WO95/00651 and
 15 shown in the enclosed sequence listing. SCCE is synonymous with human kallikrein 7 (KLK7). However, the numbering of kallikreins is not consistent between species. As discussed in example 6 the rat KLK7 in (Kroon et al. 1977) does not seem to be the rat SCCE. By the term "a SCCE variant" is meant a variant of said sequence not having exactly the amino acid sequence shown in SEQ ID NO:2, it may e.g. be a SCCE protease
 20 from another species, such as from a cow, pig, rat or mouse, or a synthetic polypeptide comprising a part of SEQ ID NO:2. The SCCE variant will generally react with antibodies raised against purified native or recombinant human SCCE and will generally have significant "SCCE activity", i.e. be a serine proteinase which can be inhibited by the same inhibitors as the spontaneous cell dissociation that can be induced in model systems with
 25 samples of cornified layer of skin incubated at neutral or near neutral pH at physiological temperature, i.e. about 37°C, as described in WO95/00651.

As can be seen from the following tables, there are significant similarities between SCCE from different species:

30

Table 2. Alignment of partial deduced amino acid sequences from different species, corresponding to residues 162-184 of human SCCE (Hansson et al.1994). In bold are shown the residues Asn-170 and Ser-176.

35	Cow SCCE	NH2...AGIPNSRTNACNGDSGGPLMCKG...	(SEQ ID NO:4)
	Pig SCCE	NH2...AGIPNSKTNACNGDSGGPLVCKG...	(SEQ ID NO:5)
	Hum SCCE	NH2...AGIPDSKKNACNGDSGGPLVCRG...	(SEQ ID NO:6)
	Rat SCCE	NH2...AGIPDSKTNTCNGDSGGPLVCND...	(SEQ ID NO:7)
	Mouse SCCE	NH2 AGIPDSKTNTCNGDSGGPLVCND...	(SEQ ID NO:8)

The bottom of the primary substrate specificity pouch (see Hansson et al., 1994) in SCCE from different species (residue no 170 in Table 2 above) contains a conserved asparagine residue, which is unique among known serine proteases. Also the sequence between this
 5 residue and the active serine residue (no. 176 in Table 2) is highly conserved. This suggests that the function, e.g. specialized catalytic properties, of SCCE is critically dependent on the mentioned asparagine residue.

Table 3 Alignment of partial deduced amino acid sequences from different species,
 10 corresponding to residues (-)7 - 27 of human SCCE (Hansson et al.1994). In bold are shown the residues adjacent to activation site (C-terminal of Lys-(-1) of Arg (-1).

Cow SCCE ..	QEDQGNK SGEKIID GVPCPRGSQPWQVALLKGSQ L HCG...	(SEQ ID NO:9)
Pig SCCE ..	QEGQDK SGEKIID GVPCGSRPWQVALLKGNQLHCG...	(SEQ ID NO:10)
15 Hum SCCEEEAQ GDKIID GAPCARGSHPWQVALLSGNQLHCG...	(SEQ ID NO:11)
Rat SCCE QGERIID GKCKEGSHPWQVALLKGDQLHCG...	(SEQ ID NO:12)
Mouse SCCE QGERIID GKCKEGSHPWQVALLKGNQLHCG...	(SEQ ID NO:13)

20

Active human SCCE is formed by cleavage C-terminal of K in the sequence KIIDG etc. This activation can be catalyzed by trypsin in vitro (Hansson et al., 1994).

Examining the amino acid sequence adjacent to this cleavage site reveals a high degree of conservation between species. The consensus sequence is G-X₁-X₂-I-I-D-G (SEQ ID
 25 NO:14), where X₁ is either aspartate (D) or glutamate (E), and X₂ is either lysine (K) or arginine (R). Aspartate and glutamate are functionally similar, both having negatively charged functional groups. The same holds true for lysine and arginine, which both have positively charged functional groups and forms sites for cleavage catalyzed by enzymes with trypsin-like primary substrate specificity. The consensus sequence adjacent to the
 30 activation site is unique among known serine proteases, suggesting an important function. It also suggests that there may exist enzymes in tissue (e.g.) epidermis, the specific function of which is SCCE-activation.

More specifically, the invention relates to a transgenic mammal or mammalian embryo
 35 having integrated within its genome a heterologous nucleotide sequence comprising at least a significant part of a nucleotide sequence coding for a protein with an amino acid sequence which has a sequence identity of at least 75% to the amino acid sequence shown in SEQ ID NO:2 and which contains the partial sequence glycine-X₁-X₂- Isoleucine-

isoleucine-aspartate-glycine (SEQ ID NO:14), wherein X_1 is aspartate or glutamate and X_2 is lysine or arginine, operably linked to a promoter that drives expression in skin.

- Preferably, the invention relates to a transgenic mammal or mammalian embryo having
- 5 Integrated within its genome a heterologous nucleotide sequence comprising at least a significant part of a nucleotide sequence coding for a protein with an amino acid sequence which has a sequence identity of at least 75% to the amino acid sequence shown in SEQ ID NO:2 and which contains the partial sequence (SEQ ID NO:15) X_3 -asparagine- X_4 - X_5 - X_6 - X_7 - X_8 -serine, wherein
- 10 X_3 is any amino acid residue, X_4 is any amino acid residue, X_5 is a cysteine residue X_6 is any amino acid., X_7 is a glycine residue, X_8 is an aspartate residue, and the serine is the active serine residue characteristic of serine proteases, operably linked to a promoter that drives expression in skin.
- 15 In alternative embodiments, the encoded polypeptide has a sequence identity of at least 80% with the amino acid sequence shown in SEQ ID NO:2, such as at least 90%, e.g. at least 95%, preferably at least 98%, e.g. at least 99%.

To determine the percent identity of two amino acid sequences or of two nucleic acids, the

20 sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as

25 the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = # of identical positions/total # of positions (e.g., overlapping positions) x 100). In one embodiment the two sequences are the same length.

30

Alignment of two sequences for the determination of percent identity can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul

35 (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990) J. Mol. Biol. 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12, to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program,

score = 50, wordlength = 3 to obtain amino acid sequences homologous to a protein molecule of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389-402. Alternatively, PSI-Blast can be used to perform an iterated search which detects
5 distant relationships between molecules. When utilizing the NBLAST, XBLAST, and Gapped BLAST programs, the default parameters of the respective programs can be used. See <http://www.ncbi.nlm.nih.gov>. Alternatively, sequence identity can be calculated after the sequences have been aligned e.g. by the program of Pearson W.R and D.J. Lipman (Proc Natl Acad Sci USA 85:2444-2448, 1998) in the EMBL database (www.ncbi.nlm.nih.gov/cgi-bin/BLAST). Generally, the default settings with respect to e.g. "scoring matrix" and "gap
10 penalty" can be used for alignment.

The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only
15 exact matches are counted.

By the term "at least a significant part of a nucleotide sequence coding for SCCE" is meant a nucleotide sequence (i.e. a DNA sequence or a RNA sequence) encoding a polypeptide having at least a part of the amino acid sequence shown in SEQ ID NO:2 and preferably
20 resulting in an abnormal phenotype as described in the following. It is contemplated that it is useful and maybe even necessary to include intron sequences when preparing a nucleotide sequence coding for a SCCE or a variant thereof, i.e. one or more of the introns present in the human scce shown in Table 1 (see also annotations to GenBank accession number AF332583 which hereby is incorporated by reference) or one or more of the
25 murine introns which may be deduced from the murine sequence. It is likely that not all of the intron sequences are necessary and that intron sequences from SCCE from other species or intron sequence from genes coding for other proteins may also be suitable and should be inserted in the nucleotide sequence coding for SCCE in a suitable manner.

30 It is contemplated that only a minor part of SCCE is necessary in order to obtain the abnormal phenotype. By the term "a significant part" is meant a nucleotide sequence encoding at least 50 amino acids of SEQ ID NO:2, e.g. at least 70 amino acids, at least 100 amino acids, at least 150 amino acids or at least 200 amino acids. These lengths are considered to be "a significant part of the peptide shown in SEQ ID NO:2". The
35 polypeptides encoded may be longer than the above stated lengths, which will then indicate the parts which are common between the polypeptides encoded and SEQ ID NO:2. Generally, however, such nucleotide sequences will comprise the major part of the nucleotide sequence shown in SEQ ID NO:1 described in WO95/00651 and shown in the

enclosed sequence listing, such as at least 500 nucleotides, e.g. at least 600 nucleotides, at least 650 nucleotides, at least 700 nucleotides, e.g. 750 nucleotides.

Such nucleotide sequences will generally hybridize with the complementary sequence to
5 nucleotide sequence SEQ ID NO: 1 or a part thereof under stringent hybridization
conditions. Within the concept of the present invention is thus a transgenic mammal or
mammalian embryo having integrated within its genome a nucleotide sequence which
hybridizes with the complementary sequence to the nucleotide sequence SEQ ID NO: 1 or
a part thereof under stringent hybridization conditions, preferably under highly stringent
10 conditions, said sequence comprising at least a significant part of a nucleotide sequence
coding for a stratum corneum chymotryptic enzyme (SCCE) or a variant thereof operably
linked to a promoter that drives expression of scce in skin. In a particularly interesting
embodiment of said transgenic mammal or mammalian embryo said promoter drives
expression of scce in epidermis. The term "stringent" when used in conjunction with
15 hybridization conditions is as defined in the art, i.e. 15-20°C under the melting point T_m , cf.
Sambrook et al, 1989, pages 11.45-11.49. Preferably, the conditions are "highly
stringent", i.e. 5-10°C under the melting point T_m . However, due to the degeneracy of the
genetic code also nucleotide sequences, which have only minor resemblance to SEQ ID
NO:1, may be able to encode a SCCE.

20

The vectors for expressing the nucleic acids having nucleotide sequences coding for a
SCCE require that the nucleic acid having a nucleotide sequence coding for a human SCCE
be "operatively linked." A nucleic acid is operatively linked when it is placed into a
functional relationship with another nucleic acid sequence. For instance, a promoter or
25 enhancer is operatively linked to a coding sequence if it affects the transcription of the
sequences. The promoter and enhancer may be the same or two different entities. The
SV40 early promoter is an example of an integrated promoter and enhancer. Operatively
linked means that the DNA sequences being linked are contiguous and, where necessary to
join two protein-coding regions, contiguous and in reading-frame. By the term "a SCCE
30 construct" is meant a nucleotide sequence comprising at least a significant part of a
nucleotide sequence coding for a stratum corneum chymotryptic enzyme (SCCE) or a
variant thereof operably linked to a promoter that drives expression of scce in skin or part
of the skin. In particular a SCCE construct that comprise a promoter that drives expression
of scce in epidermis is contemplated.

35

In a preferred embodiment according to the present invention, the promoter is a
ubiquitous promoter. By the term "ubiquitous promoter" is meant a promoter that is active
in many different cell types of the host organism in contrast to a promoter whose
expression is specific for one or a few target cell types (a tissue-specific promoter). An

- example of "ubiquitous" promoter" is the SV40 promoter and variations thereof such as the SV40 early promoter. Other examples of ubiquitous promoters are other viral promoters such as polyoma early promoter, retroviral long terminal repeats (5' -LTR) adenovirus promoters, and house keeping cellular genes such as β -actin, and ribosomal protein promoters. The promoter is preferably a heterologous promoter. It is contemplated that constitutive viral promoters, such as polyoma early viral promoter, Epstein Barr virus promoter and retroviral long term repeat LTR promoters will be useful in the construction of transgenic mammals according to the invention.
- 10 An important embodiment of the invention relates to a transgenic mammal or mammalian embryo selected from the group consisting of rodents, such as mice, rats and rabbits, cats and dogs. A preferred embodiment of the invention is a transgenic mammal or mammalian embryo, which is selected from the group consisting of mice.
- 15 Preferably, the transgenic mammal or mammalian embryo according to the invention comprises a heterologous nucleotide sequence comprising a significant part of DNA sequence coding for human SCCE as shown in SEQ ID NO:1. The transgenic mammal or mammalian embryo according to the invention preferably comprises a nucleotide sequence coding for a significant part of the peptide shown in SEQ ID NO. 2 as defined above. In preferred embodiments, the DNA sequence codes for the peptide corresponding to amino acid no. -7 through no. 224 of the amino acid sequence shown in SEQ ID NO. 2, the peptide corresponding to amino acid no. 1 through no. 224 of the amino acid sequence shown in SEQ ID NO. 2 or the peptide shown in SEQ ID NO. 2. Presently preferred embodiments relate to transgenic mammals or mammalian embryos according to the invention, wherein the DNA sequence comprises the DNA shown in SEQ ID NO. 1 or the DNA sequence is SEQ ID NO:1.
- 20 In an important embodiment of the invention, the transgenic mammal or mammalian embryo according to the invention exhibits an abnormal phenotype, such as an abnormal skin phenotype and/or a predisposition for cancer, e.g. a predisposition for ovarian cancer. Preferably, the mammal or mammalian embryo according to the invention exhibits an abnormal skin phenotype resembling one or more inflammatory skin diseases characterized by epidermal hyperkeratosis, acanthosis, epidermal and/or dermal inflammation and/or pruritus, e.g. inherited skin diseases with epidermal hyperkeratosis, 35 ichthyosis vulgaris, psoriasis, chronic atopic dermatitis or chronic eczema. The mammal or mammalian embryo according to the invention may thus exhibit epidermal hyperkeratosis, acanthosis, epidermal/dermal inflammation and/or pruritus.

The invention further relates to a method for making a transgenic non human mammal or mammalian embryo having integrated within its genome a heterologous nucleotide construct comprising at least a significant part of a nucleotide sequence coding for a stratum corneum chymotryptic enzyme (SCCE) or a variant thereof operably linked to a promoter that drives expression of *scce* or a variant thereof in skin, the method comprising

(a) constructing and amplifying a nucleotide sequence comprising at least a significant part of a nucleotide sequence coding for a stratum corneum chymotryptic enzyme (SCCE) or a variant thereof operably linked to a promoter that drives expression of *scce* or a variant thereof in skin,

(b) introducing into a non-human cell said heterologous nucleotide construct,

(c) using said cell or the progeny of said cell to create a number of putative transgenic non-human mammals or mammalian embryos,

(d) selecting said non-human mammal or mammalian embryo having said heterologous nucleotide construct integrated within its genome.

In one embodiment of the invention said transgenic mammal or mammalian embryo have integrated a nucleotide sequence coding for human SCCE or a variant thereof as defined above operably linked to a promoter that drives expression of *scce* in epidermis. In a preferred embodiment, the invention relates to a method for making a transgenic mammal according to the invention, where the mammal exhibits an abnormal phenotype as defined above. The method comprises introducing the SCCE-construct into an ovum or embryo of the mammal by physical, chemical or viral means, e.g. by electroporation, transfection, microinjection or viral infection. In a preferred embodiment of the invention, the SCCE-construct is microinjected into an ovum or embryo of the mammal or into embryonal stem cells of the mammal. In a preferred embodiment, the method according to the invention comprises microinjecting the SCCE-construct into C57BL/6JxCBA-f2 mice ovum or embryos. The method preferably further comprises breeding the resulting mice with C57BL/6JxCBA or with C57BL/6J to obtain transgenic litter and stable mouse lines. Such stable cell lines derived from the transgenic mammals comprising a SCCE construct as described above are contemplated to be useful for e.g. high throughput screening of suitable compounds as described in the following.

Another aspect of the invention relates to the use of the transgenic mammal or mammalian embryo according to the invention as a model for the study of disease with the aim of improving treatment, relieve or ameliorate a pathogenic condition, for development

or testing of a cosmetic or a pharmaceutical formulation or for the development of a diagnostic method. A preferred use according to the invention of said transgenic mammal or mammalian embryo is as a model for a skin disease or a model for cancer such as ovarian cancer.

5

An important aspect of the invention relates to a method of screening for a compound or composition effective for the prevention or treatment of an abnormal or unwanted phenotype, the method comprising

- 10 (a) administering a compound or composition to a transgenic mammal having integrated within its genome a nucleotide sequence coding for at least a significant part of SCCE operably linked to a promoter that drives expression of the scce in an organ, wherein the rodent exhibits an abnormal phenotype,
- 15 (b) evaluating the appearance of the relevant organ and/or the behavior of a mammal treated according to step (a), and
- (c) comparing the appearance of the relevant organ and/or the behavior of a treated rodent with an untreated control mammal.

20

An important aspect of the invention relates to a method of identifying a compound or composition effective for the prevention or treatment of an abnormal or unwanted phenotype, the method comprising

- 25 (a) administering a compound or composition to a transgenic mammal having integrated within its genome a nucleotide sequence coding for at least a significant part of SCCE operably linked to a promoter that drives expression of the scce in an organ, wherein the rodent exhibits an abnormal phenotype,
- 30 (b) evaluating the appearance of the relevant organ and/or the behavior of a mammal treated according to step (a), and
- (c) comparing the appearance of the relevant organ and/or the behavior of a treated rodent with an untreated control mammal.

35

(d) identifying the compound or composition as being effective for the prevention or treatment of the abnormal or unwanted phenotype.

- In preferred embodiments, the organ is the ovaries or the skin, or more preferably the epidermis. A presently preferred embodiment of the invention relates to a method of screening for or identifying a compound or composition effective for the prevention or treatment of itchy inflammatory skin diseases such as ichthyosis vulgaris, prurigo nodularis, neurodermatitis, lichen planus. Other preferred embodiments of the invention relate to a method of screening for or identifying a compound or composition effective for the prevention or treatment of chronic atopic dermatitis and psoriasis. Also, the invention relates to a method according to the invention for screening of a cosmetic composition.
- 10 Another important aspect of the invention relates to a method of preparing a pharmaceutical composition which comprises: i) identifying a compound or composition as being effective for the prevention or treatment of an abnormal or unwanted phenotype using a method according to the present invention, and ii) mixing the compound with a pharmaceutically acceptable excipient or diluent.
- 15 In particular, the invention relates to a cosmetic or pharmaceutical composition that has been discovered or developed by use of the above methods comprising use of a transgenic mammal or mammalian embryo as described above. In this respect the invention relates to pharmaceutical formulations for systemic treatment as well as for cosmetic and
- 20 pharmaceutical formulations for topical application on the skin or epithelium.
- Yet a further aspect of the invention relates to a method of treating or preventing an abnormal or unwanted phenotype which method comprises administering to a patient suffering from such an abnormal or unwanted phenotype a pharmaceutical composition
- 25 prepared according to a method of the present invention.
- A preferred embodiment of the invention relates to a method of treating or preventing itchy inflammatory skin diseases such as ichthyosis vulgaris, prurigo nodularis, neurodermatitis, lichen planus. Other preferred embodiments of the invention relate to
- 30 methods of treating or preventing chronic atopic dermatitis and psoriasis.

LEGEND TO FIGURES

Figure 1.

- Organization of the human and murine structural genes and the recombinant *sv40e/hscce* gene. The six exons are indicated as black boxes. The translational start sites, located in
- 35 exon 2, are indicated with "ATG", and the stop codons in exon 6 with "TAA". Also the position of the *sv40e* transcriptional regulatory element in the construct used to generate the transgenic animal is indicated by an arrow.

Figure 2
pS99.

5 Figure 3.

A: Real time quantitative PCR analyses of recombinant human *scce* mRNA in various tissue preparations from the transgenic lines #1010 (*black bars*) and #107 (*empty bars*).

Analyses in triplicate were carried out on RNA samples comprising pooled material from three animals from each line. The murine acidic ribosomal phosphoprotein P0 was used as

10 Internal standard. Mean and SD.

B. ELISA-analyses of SCCE-protein in various tissues from the transgenic lines #1010 (*black bars*) and #107 (*empty bars*), and non-transgenic siblings (*gray bars*). Analyses in triplicate were carried out on pooled extracts from three animals from each line and

15 controls. Mean and SD.

Figure 4

Pro-SCCE and active SCCE in skin from #1010 *scce*-transgenic mice. *Hu* = extract of human plantar stratum corneum; *Tg* = extract of skin from #1010 transgene; *Wt* =

20 extract of skin from wild type littermate. Approximately 0.1 g of mouse skin was homogenized in 10 ml of 1 M acetic acid and extracted over night at 4 °C. After clearing by centrifugation extracts were aliquoted, lyophilized, and resolubilized in electrophoresis sample buffer.

25 A: Immunoblot with SCCE-specific antibodies, reduced samples. Arrowheads denote, from top to bottom, glycosylated pro-SCCE, mixture of unglycosylated pro-SCCE and glycosylated SCCE, and unglycosylated SCCE. Amount of sample applied corresponding to 0.1 mg and 4.5 mg of skin for Tg and Wt, respectively.

30 B: Zymography in 12.5% acrylamide gel with 1% casein; non-reduced samples. Amount of sample applied corresponding to 0.4 mg and 4.5 mg of skin for Tg and Wt, respectively. Arrow denotes SCCE.

To the far left (marked by asterisks) molecular weight markers; from top 106, 81, 47.5,
35 35.3, 28.2, and 20.8 kDa respectively

Figure 5.

Scratching behavior of scce-transgenic (#1010) mice. Twenty one mice, (11 transgenes, 5 females; 10 wild type litter mates, 2 females) were observed every fifth day for 45 days, starting when the mice were 5-6 weeks of age. At each observation point mice were

5 transferred to individual cages, and episodes of scratching with hind or front paws were counted during three 5-min periods with 2.5 min lapsing from the transfer to the cage to the first counting, and between counting periods. The results for the three observation periods were pooled and the number of episodes of scratching per min calculated. In A the number of episodes of scratching (mean and SEM for all animals in each group) is shown,

10 In B the percentage of animals with at least one episode of scratching per min is given. ■ (square) = #1010 transgenic mice; ▲ (triangle) = wild type litter mates.

Figure 6.

Histology and SCCE-immunohistology of skin from scce #1010 transgenic mouse and

15 control; comparison with normal human skin and chronic lesion of atopic dermatitis. Formaldehyde fixed and paraffin embedded samples. A-B stained with hematoxylin and eosin. C-F Immunoperoxidase staining with SCCE-specific antibodies, contra-staining with hematoxylin. A and C: #1010 transgenic mice, 5 weeks of age. B and D: non-transgenic littermate. E: Atopic dermatitis. F: Normal human skin. Bar = 50 μ m.

20

Figure 7.

The effect on itch in scce-transgenic mice of the glucocorticoid triamcinolone acetonide. Squares = triamcinolone acetonide, n = 4; triangles = controls (saline), n = 6.

* = statistically significant difference ($p < 0.05$) between controls and treated group.

25

Figure 8.

The effect on itch in scce-transgenic mice of the antihistamine loratidine. Black bars = loratidine (n = 7); White bars = controls (n = 7); mean and SE.. There were no statistically significant differences in frequency of scratching between treatment group and

30 control group.

EXAMPLES

The following examples are provided for illustration and are not intended to limit the invention to the specific examples provided.

35 EXAMPLE 1.

Isolation and cloning of the human SCCE gene.

The human SCCE gene was isolated from a human leukocyte genomic library cat. no. HL 1111 j lot # 3511 (Clontech, CA) by using cDNA probes derived from the human *scce* cDNA. A 253 bp cDNA fragment was amplified from pS500 (Hansson et al., 1994) by PCR using SYM3300 (5'-GGTGGCCCTGCTCAGTGGCA-3') (SEQ ID NO: 16) and SYM3301 (5'-
5 CACCATGGATGACACAGCCTGG-3') (SEQ ID NO: 17), ³²P-labelled by random priming using oligo-labelling kit (Amersham, UK) and used as a probe for screening. The fragment covers bases 149 to 401 of the published human SCCE cDNA sequence (Hansson et al., 1994). Approximately 5x10⁵ plaques were screened. Filters were prepared, prehybridized and hybridized at 65 °C, and washed at 65 °C and 25°C in accordance with the membrane
10 manufacturers recommendations (Colony/Plaque Screen™ hybridization transfer membranes DuPont NEN, MA). Filters were exposed to Hyperfilm-MP (Amersham, UK). After three rounds of screening, individual positive clones were selected, and phage DNA was isolated using standard techniques (Sambrook et al., 1989). Phage DNA was digested with several restriction enzymes and Southern blotting was performed using three different
15 probes. First, the 253 bp 5'-fragment described above was used. Second, a 618 bp 3'-noncoding cDNA fragment was used as a probe. The fragment was amplified by PCR using pS501 as template, forward primer SYM3302 (5'-AATAAAGAAACACAAAACCC-3') (SEQ ID NO: 18) and reverse primer SYM3418 (5'-TGTAATATCATTGTGGGC-3') (SEQ ID NO: 19). pS501 is a plasmid containing 1888bp human SCCE cDNA isolated from a λgt11
20 keratinocyte cDNA library ligated into EcoRI site of pUC19 and covers cDNA with coding sequence from amino acid four over the stop codon and contains 868 bp extra untranslated 3' sequence. Finally, a 897 bp fragment containing the entire coding SCCE cDNA sequence was isolated from EcoRI/DraI digested pS500 (Hansson et al., 1994) and used as a probe. Probes were labelled and hybridization was performed as described
25 above. Two positive clones were digested with SalI and cloned into pUC19 generating pS772 and pS773. In order to determine the DNA sequence of the human SCCE gene, several overlapping subclones of pS772 and pS773 were generated in pUC19. Subclones were sequenced using the dideoxy chain termination method (T7 sequencing kit, Pharmacia, Sweden or the Dye Terminator Cycle Sequencing Ready Reaction kit, PE
30 Applied Biosystems, CA) with M13 forward and reverse primers as well as specific primers..

Isolation and cloning of the mouse SCCE gene.

To isolate the murine SCCE gene, a 430 bp cDNA fragment was isolated from HindIII/SalI digested pS506 (Bäckman et al., 1999). The fragment was ³²P-labelled by random priming using oligo-labelling kit (Amersham, UK), and used as probe to screen a 129SVJ Lambda
5 Fix II genomic library (Stratagen, CA). Approximately 1x10⁶ plaques were screened. The blots were prepared, prehybridized and hybridized at 65 °C as described by the manufacturer (Colony/Plaque Screen™ hybridization transfer membranes DuPont NEN, MA). Washing was also performed as described in the hybridization protocol and membranes were exposed to Hyperfilm-MP (Amersham, UK). Individual positive clones
10 were selected after three rounds of screening. A few positive plaques were further investigated by PCR using SYM4118 (5'-GGATGTGAAGCTCATCTC-3') (SEQ ID NO: 20) and SYM4121 (5'-TGGAGTCGGGGATGCCAG-3') (SEQ ID NO: 21). Obtained PCR products were analyzed by Southern blotting using the probe and conditions described above. Phage DNA was isolated from confirmed positive clones using standard techniques. Southern
15 analysis was performed on phage DNA digested with a panel of restriction enzymes using the probe and conditions described above. One of the positive clone was digested with SacI, and a fragment of ~15.5 kb was isolated and cloned into pUC19 generating pS714. Several overlapping subclones of pS714 were generated in pUC19. DNA sequencing of the subclones were performed as described for the human SCCE gene.

20

Primer extension analysis.

Two exon 1-specific oligonucleotides; one human and one mouse, were used to determine the 5'-prime ends of the human and murine SCCE transcripts. To determine the start of the human transcript (Ausubel et al.) a PCR fragment of 346 bp was amplified from
25 plasmid pS779 (A subclone covering 5'-untranslated sequence, exons 1-3, 5'-end of exon 4 and introns 1-3) using forward primer SYM4720 (5'-GGGAGGGTGGAGAGAGAGAGTGTCAGTG) (SEQ ID NO: 22) and reversed primer SYM4899(5'-AGTCTAGGCTGCAGCCCCTAC-3') (SEQ ID NO: 23). To prepare a 245 bp ³²P-dCTP labelled single stranded probe, primer hEXON1 (5'-CTCGAGGGATCTGATGTGATCC-3') (SEQ ID NO: 24) was
30 annealed to the amplified fragment and labelling was performed using the Prime-A-Probe™ DNA labelling kit (Ambion, Austin, Texas, USA). 10⁶ cpm labelled probe was mixed with 50 µg total RNA from human skin. Hybridisation and S1 treatment was performed using S1-Assay™ (Ambion, Austin, Texas, USA). The final product was analyzed on a sequencing gel. Dideoxy sequencing reactions of pS779 primed with oligo hEXON1 were used as size
35 markers.

The start of the murine transcript was determined using SacI linearized pS721 (A subclone covering 5'-untranslated sequence, exons 1-3, Introns 1-2 and 5'-end of intron 3). A 225 bp ³²P-dCTP labelled single stranded probe was prepared by annealing of primer mEXON1

(5'-CTGGGAGTGACTTGGCGTGGCTCT-3') (SEQ ID NO: 25) to the linear plasmid and labelling was performed using the Prime-A-Probe™ DNA labelling kit (Ambion, Austin, Texas, USA). 10⁶ cpm labelled probe was mixed with 50 µg total RNA isolated from mouse tail. Hybridization and S1 treatment was performed using S1-Assay™ (Ambion, Austin, Texas, USA). The obtained product was analyzed as described above using sequencing reactions of pS721 primed with oligo mEXON1 as size markers.

RESULTS

(Nucleotide sequences in Gene Bank: Human *scce* (hSCCE): accession number AF332583; Murine *scce* (mSCCE): Accession number AF339930.)

10

A human leukocyte EMBL3λ genomic library was screened using a probe made from the coding region of human *scce* cDNA (Hansson et al., 1994) individual positive clones were identified. Based on restriction analysis and Southern blotting two overlapping clones, 12 and 15.5 kbp in size respectively, were selected. These clones were spanning the entire *scce* cDNA. The genomic structure of the human *scce* structural gene comprises six exons and spans approximately 8 kb. The organization and sizes of exons and introns are shown in fig 1. The translation initiation site (designated +1) is found 60 nucleotides downstream the 5'-end of exon 2.

20 To isolate the murine *scce* gene, a SVJ129 genomic λFIX™ II library was screened using a probe corresponding to the coding region of murine *scce* cDNA (Bäckman et al.). Among the isolated clones one harboring about 15.5 kb was shown to contain the entire murine structural gene. A major part comprising 11770 nucleotides was sequenced and the murine structural *scce* gene was shown to be shorter than the human gene. However, the overall organization reveals several similarities with the human homologue and also consists of six exons (figure 1). Since the polyadenylation site of the murine cDNA has not been identified so far, the exact size of exon 6 could not be determined. However, a putative poly A site was localized 136 bp 3'-prime of the stop codon. The translation initiation site (designated +1) is found in exon 2, 39 nucleotides 3' of the Intron 1 3'-intron-exon junction.

30

To determine the 5' ends of the human and murine transcripts primer extension studies were performed. Sequence analysis of the human cDNA (exon1, unpublished results) revealed that the major human primer extension product extends to the nucleotide identified at the 5' end of the human cDNA sequence (Hansson et al). Analysis of the two major products obtained from the murine gene by primer extension reveal two different transcription starts. One product extends to one nucleotide 5' of the murine SCCE cDNA 5' end (Bäckman et al.). The other product extends to one nucleotide 3' of the cDNA 5' end.

EXAMPLE 2*Generation and gross phenotypic characterization of of scce transgenic mice with the hscce gene under control of the SV40e promoter*

5

Construction of transgene.

In order to overexpress the human genomic scce structural gene under transcriptional regulation of the simian virus 40 early, *SV40e*, enhancer and promoter, an expression vector was constructed. The scce genomic DNA was modified by insertion of *HindIII* linkers
10 20 bp upstream of the start codon and 4.8 kb downstream of the stop codon, respectively. The resulting *HindIII* scce fragment was the ligated to a 325 bp *BamHI/HindIII* fragment of pS99 (Figure 2) containing the *SV40e* enhancer and promoter elements and cloned into pBluescript SK+/- (Stratagene) resulting in pAM119. For gene transfer, the plasmid pAM119 was digested with *BamHI* and *ClaI* and the *SV40e/scce* fragment of about 10.7 kb
15 was isolated and purified by electroelution before microinjection into one-cell stage mouse ova.

Transgenic mice were generated in C57BL/6JxCBA-f2 embryos by standard microinjection procedures (Hogan et al, 1986). The 10,7 kb *SV40e/scce* fragment to be injected was
20 excised from the pAM119 plasmid by restriction enzyme cleavage with *BamHI* and *ClaI*, separated by gel electrophoresis through an agarose gel, cut out, isolated using isotachopheresis and precipitated with ethanol.

Identifying transgenic animals.

25 To identify transgenic animals, DNA was extracted from tail biopsies of 3-wk old mice and the DNA was analyzed either by Southern blot analyses or with PCR as described in Ausubel et al. The PCR analysis was performed using primers specific for human scce (IE2: 5'-GCT CTC CCA TTA GTC CCC AGA GA-3' (SEQ ID NO: 26), MJ2: 5'-CCA CTT GGT GAA CTT GCA CAC TTG-3' (SEQ ID NO: 27)). Briefly, the PCR was performed with an initial
30 denaturation at 95 °C for 10 min., followed by 28 cycles of denaturation at 95 °C for 30 sec, annealing at 65 °C for 30 sec, elongation at 72 °C for 45 sec and finally by a 10 min elongation at 72 °C. The resulting PCR products were analyzed by standard agarose gel electrophoresis using a 1 % agarose gel and visualizing the DNA with Ethidium bromide as described in Ausubel et al., 1992. Three transgenic lines (#103, #107 and #1010) were
35 established by breeding heterozygous mice with C57BL/6JxCBA.

RESULTS

As expected, initial characterization of the three lines revealed very large differences in levels of recombinant *scce* expression (see example 3). In line #1010, which has the highest *hsce* transcript levels, skin abnormalities were apparent, whereas in the two other lines no skin changes or other gross phenotypic deviations could be observed. For further detailed comparative studies of the #1010 transgenics one of the lines with apparently normal phenotype (#107) and non-transgenic littermates were included as controls. Macroscopic phenotypic changes in transgenic #1010 animals were noted as a loss of hair from a narrow zone around the eyes in mice 4-5 weeks of age. In older mice there was an apparent thinning of body hair in general, and a luster-less appearance of the coat. On the back the skin surface was sometimes covered with fine scales. From the age of 5-6 weeks and onwards several of these transgenic animals showed signs of itch with scratching, the frequency of which increased with time.

Diagnostic necropsies with routine histological analyses were carried out on transgenic mice of the #1010 and #107 C57BL/6JxCBA lines, and of littermate controls. Tissues examined were brain, cerebellum, intestines (duodenum/jejunum, ileum, colon, rectum), and skin. In some animals 3 weeks of age heart, liver, lung, salivary gland, spleen, thymus and thyroid were also examined. In littermate controls (for #1010: 3 weeks, n = 5; 5 weeks, n = 5; for #107 5 weeks, n = 3) and transgenic mice of the #107 line (5 weeks n = 3) no significant macro- or microscopic abnormalities were observed. In transgenic animals from line #1010 abnormalities were found in the skin, but in no other organs or tissues. In mice 3 weeks of age (*i.e.* before phenotypic changes could be observed by inspection of living animals) skin changes were found in all animals examined (n = 4). These changes included mild to moderate epidermal hyperplasia and hyperkeratosis and a mild cellular inflammatory reaction with mixed leukocytes in the upper dermis. In animals 5 weeks of age (n = 4) the skin abnormalities were of the same type but more pronounced with a marked acanthosis-like hyperplasia and a hyperkeratosis of the epidermis which was mainly orthokeratotic. In addition, the number of mast cells in the dermis was increased in some of the animals. Leukocyte invasion of the epidermis was occasionally found and then manifested as small groups of granulocytes within the thickened cornified layer, which at these sites was parakeratotic.

EXAMPLE 3.

*Determining the expression of *scce*-mRNA, SCCE protein in mice and catalytically active SCCE in SV40e-scce-transgenic mice.*

Isolation of tissues.

Tissue specimens were collected at different ages and immediately frozen and stored in liquid nitrogen until analyzed.

5 RNA Isolation and cDNA synthesis and Real Time Quantitative PCR.

From 50-300 mg of the isolated tissues liver, skin, lung, brain, small intestine, colon, and ear, total RNA were prepared using RNA STAT-60™ (Tel-Test "B", Inc., Friendswood, TX, USA) according to the manufacturer. 50µg of each RNA preparation were DNase treated using RQ1 DNase (Promega, Madison, WI, USA) according to Ausubel et al. About 1,6 µg
10 total RNA from each tissue was used for cDNA synthesis. Three RNA samples from animals with same genetic background and tissue were mixed and cDNA synthesis was made using Superscript™ Preamplification System for First Strand cDNA Synthesis (Life Technologies, Inc. Gaithersburg, MD, USA) according to the manufacturer. The cDNA synthesis was primed using Oligo d(T)₁₂₋₁₈ primer. The synthesized cDNA were diluted 100x in water prior
15 to real time quantification. Real time quantification was performed three times on each cDNA. Primer and probe for real time quantification of transgenic human SCCE were designed over exons four and five where the sequence between human and murine SCCE show little (less) homology. The forward primer (5'-GCGAACCCCTGGAACAA-3') (SEQ ID NO: 28) covers the position 427 – 444 of the human cDNA sequence (ref. Hansson et al) in
20 exon four. The reverse primer (5'-ACATCCACGCACATGAGGTCA-3') (SEQ ID NO: 29) covers the position 490 – 510 of the human cDNA sequence in exon five. The real time amplification probe (5'- CCTGTACTGTCTCCGGCTGGGGCACTACC- 3') (SEQ ID NO: 30) covers the position 445 – 473 of the human cDNA sequence in exon four, and was labelled with the reporter fluorescent dye FAM in the 5'- end and the quencher fluorescent dye
25 TAMRA in the 3'-end. The amplification of PCR products and real time detection were performed in ABI Prism 7700 Sequence Detection System (PE Applied Biosystems, Foster City CA, USA). Amplification of a part of murine acidic ribosomal phosphoprotein P0 (ACC# X15267) was used as endogenous control for the real time quantitation studies. The relative quantitation was calculated according to the formula $2^{-\Delta\Delta C_T}$, where ΔC_T is the
30 difference in C_T values between the target and the endogenous control (User Bulletin #2, PE Applied Biosystem).

SCCE-specific polyclonal antibodies.

Polyclonal antibodies to recombinant human SCCE were prepared and affinity purified as
35 described by Sondell et al. (Sondell et al. 1996). These antibodies are reactive towards human SCCE and pro-SCCE, as well as murine SCCE.

Tissue preparation, ELISA, immunoblotting and zymography.

Tissue extracts for ELISA were prepared by homogenization of 200-400 mg frozen tissue in 1 ml dH₂O containing a mixture of protease inhibitors (Complete™ Protease Inhibitor

Cocktail Tablets cat. no. 1836153, Boehringer Mannheim, Germany), followed by centrifuging at 20 000 x g for 30 min at 4 °C. Protein concentrations was determined by reaction with bicinchoninic acid with bovine serum albumin as standard

For SDS-polyacrylamide gel electrophoresis approximately 0.1 mg of mouse skin was
5 homogenized in 10 ml of 1 M acetic acid and extracted over night at 4 °C. After clearing by centrifugation extracts were aliquoted, lyophilized, and resolubilized in electrophoresis sample buffer for zymography. SDS-polyacrylamide gel electrophoresis, zymography, and immunoblotting were carried out as described (Ekholm et al. 2000).

For ELISA polystyrene microtiter plates were coated with 100 µl of SCCE-specific rabbit
10 polyclonal antibodies at a concentration of 7 µg/ml prepared in coating buffer (0.1 M Na₂CO₃, 0.02 % NaN₃ (w/v), pH 9.6). After incubation over night at 4 °C on a wobbling table, the plate was washed once with washing buffer (10 mM NaH₂PO₄, 0.15 M NaCl, 0.05% (v/v) Tween 20, pH 7.2). Thereafter, 200 µl blocking buffer (10 mM NaH₂PO₄, 0.15 M NaCl, 0.1% (w/v) Bovine Serum Albumine (BSA), pH 7.2) was added to each well and
15 the plate was incubated at 37 °C for 1h. The plate was washed three times with washing buffer, 50 µl of sample (or standard) in dilution buffer (10 mM NaH₂PO₄, 0.15 M NaCl, 0.1% (w/v) BSA, 0.05% (v/v) Tween 20, pH 7.2) was added to each well and the plate was incubated for 1h at 37 °C. Plates were washed three times with washing buffer, and further prepared by adding 100 µl/well of SCCE-specific antibodies (7 µg/ml) labelled with
20 alkaline phosphatase. Plates were incubated for 1h at 37 °C before washing three times with washing buffer. Development was performed by addition of 100 µl freshly prepared substrate solution (2 tablets of phosphatase substrate (Sigma104 phosphatase substrate tablets) dissolved in 10 ml 0.1 diethanol amine-HCl, 0.5mM MgCl₂, pH 9.8). Plates were incubated in the dark for 30 min at room temperature. Finally, 25 µl stop solution was
25 added to each well and the absorbance was read at 405 nm. For quantitation recombinant human pro-SCCE (Hansson et al) was used as standard.

RESULTS

Real Time Quantification of human SCCE transcribed in transgenic mice.

- In order to investigate if the difference in skin phenotype between #1010 ABD #107
- 5 transgenic lines expression of *hscce* mRNA in various tissues was analyzed by quantitative RT-PCR. The results are shown in Fig. 3A.
- Six different tissues were analyzed. The analyses showed significantly higher expression of *hscce* in all tissues examined for transgenic mice of the #1010 line as compared to mice of the #107 line and non-transgenic littermates. The highest relative *hscce* mRNA levels were
- 10 found in the Intestines and lungs, but the difference in *hscce* expression between the two transgenic lines was most pronounced for skin, in which the relative level of *hscce* mRNA was about 24 times higher in #1010 mice than in #107 mice.

ELISA

- 15 Analyses of SCCE protein with ELISA (Fig. 4B) showed values close to or below the detection limit for tissues from transgenics of the #107 line and normal controls. In #1010 transgenics SCCE protein was readily detectable in several tissues including skin, intestines, and lung, the relative level (ng/mg) being highest in the skin.

Immunoblotting and zymography

- Immunoblotting with SCCE-specific antibodies corroborated the ELISA-results. In extracts of skin of control mice small amounts of a component with molecular mass similar to human SCCE was detected, whereas a component with the same relative molecular mass detected in high amounts in skin extracts from #1010 transgenic mice (Fig. 4A).
- 25 Zymography in casein-containing acrylamide gels showed that the extracts of skin from #1010 transgenics contained a proteolytic enzyme with the same electrophoretic mobility as human SCCE. A corresponding enzyme could not be detected in control extracts (Fig. 4B; the amounts of active murine SCCE are too low to be detected under the experimental conditions used). These results suggest that a fraction of the human pro-SCCE produced in
- 30 skin of #1010 transgenics is converted to proteolytically active enzyme. This was supported also by the immunoblotting experiments (Fig. 3A), where a component corresponding to active human SCCE was labelled with the antibodies. In addition to SCCE, the skin extracts of #1010 transgenics contained increased amounts of a proteolytic enzyme not related to SCCE. The nature of this enzyme is presently not known.

35

CONCLUSION

The expression of *hscce* in various tissues at the RNA level was higher in #1010 transgenic mice than in the #A107 transgenic mice. The difference between transgenics from the two lines was even more pronounced as regards expression of SCCE-protein. In skin of #1010

transgenic mice high amounts of SCCE protein could be detected with Immunoblotting. The majority of this protein appeared to be pro-SCCE, but also active SCCE could be detected in increased amounts.

5 EXAMPLE 4

Scce-transgenic mice as models for studies of inflammatory skin diseases and itch

Three male transgenic #1010 mice were mated with wild type C57BL/6J females, resulting in 6 litters with a total of 40 mice. Of these 19 (8 transgenics) were sacrificed at the age of 7-8 weeks and 21 (11 transgenics) were followed to the age of 13-14 weeks. In the latter group scratch movements with the legs were quantified.

Macroscopic phenotypic changes in transgenic #1010 animals were noted as a loss of hair from a narrow zone around the eyes in mice 4-5 weeks of age. In older mice there was an apparent thinning of body hair in general, and a luster-less appearance of the coat. On the back the skin surface was sometimes covered with fine scales. From the age of 5-6 weeks and onwards several of these transgenic animals showed signs of itch with scratching, the frequency of which increased with time.

20

Itching behavior

Of the 11 transgenic mice followed for 13-14 weeks 8 animals (73%) showed signs of itch (at least one period of scratching with hind or fore paws per minute) at the age of 10-11 weeks. The frequency of scratching varied among the observed animals; whereas some animals showed weak or moderate signs of itch, other animals spent most of their time scratching (Fig. 5). Up to the age of 3 weeks there was no statistically significant difference in weight between transgenic and normal animals. With increasing age there was a tendency towards lower weights among transgenics. At the age of 14-15 weeks there was a 7-10% reduction in weight in transgenics as compared to wild-type litter mates (mean for males 27.0 gm versus 30.0 gm; $p = 0.022$; mean for females 21.7 gm versus 23.5 gm; $p = 0.033$).

Histological analysis

For histology and immunohistochemistry (Ekholm et al. 1998 and Sondell et al. 1996) samples were either formaldehyde fixed and paraffin embedded according to routine protocols or frozen after fixation for 2 h in formaldehyde.

Upon sacrifice of the animals tissues (dorsal skin, large and small intestines, and lung) were prepared for microscopic analyses. The preliminary microscopic examination of routinely processed skin samples was carried out blindly (the examiner was not informed

about genotype or scratching behavior). In all cases but one, transgenics could be differed from wild type controls, the most prominent difference being the thickened epidermis in transgenic animals. Epidermal thickness was 55 μm (SD = 21 μm ; n = 19) for transgenic animals, and 15 μm (SD = 2.6 μm ; n = 21; p < 0.001) for controls. There was no statistically significant difference in epidermal thickness between younger (7 – 8 weeks) and older (13-14 weeks) transgenic animals. Other prominent and frequent histological findings in skin of transgenic animals as compared to controls (Fig. 6 A-B) were a marked hyperkeratosis, an increased cellularity of the dermal part of the skin, and increased epithelial thickness of adnexal structures (hair follicle walls and sebaceous glands and ducts). The increase in number of cells in the connective tissue was only partially due to lymphocytes and granulocytes; there appeared to be an increase also in the number of fibroblasts and/or histiocyte-like cells. Tolouidine blue staining showed increased number of dermal mast cells in some transgenic animals (results not shown). In routine stained sections no differences could be found between transgenics and controls for any of the other organs examined (results not shown).

Immunohistochemistry

Immunohistologic analyses of skin samples from #1010 transgenic animals and littermate controls with SCCE-specific antibodies showed strong labelling of keratinocytes in suprabasal parts of interfollicular epidermis in transgenics, including the thickened cornified layer. In hair follicles and sebaceous ducts only luminal parts, including the cornified lining of follicles and ducts, were stained (Fig. 6C). This was in marked contrast to basal cells of interfollicular epidermis and the major parts of hair follicles and sebaceous ducts and glands, where no or very weak labelling by the antibodies was seen. In controls there was a relatively weak labelling of a narrow zone of interfollicular epidermis close to the transition to the stratum corneum, of the stratum corneum, and of luminal parts of hair follicles (Fig. 6D). This pattern was similar to that previously described for normal human epidermis (Ekholm et al 1998). With immunofluorescence microscopy on formaldehyde fixed frozen samples similar results (not shown) were obtained.

In the intestines SCCE-specific labelling was seen only in transgenics and in irregularly distributed epithelial cells. Stained cells were more numerous at the tips of villi in the small intestine and in the luminal parts of colonic epithelium. In the lungs of transgenics apical parts of bronchiolar epithelial cells were weakly labelled. At higher antibody concentrations there appeared to be a diffuse labelling also of the alveolar epithelium (results for intestines and lung not shown).

Comparison with diseased human skin.

Skin biopsies from human volunteers and patients were taken after informed consent and with the approval of the Human research ethics committee, Umeå University. Biopsies were taken from chronic eczematous lesions on the flexural sides of lower arms of five adults with atopic dermatitis and processed for microscopy as above. Biopsies from corresponding sites were obtained from volunteers. In routine stained sections (not shown) the lesions showed, as expected, marked acanthosis, hyperkeratosis, and a sparse dermal infiltrate consisting mainly of lymphocytes. Immunohistology with SCCE-specific antibodies showed a drastic increase in the number of labelled suprabasal cell layers as compared to controls (Fig. 6 E-F). As regards the acanthosis, hyperkeratosis, and pattern of SCCE-specific staining the differences seen between lesional and normal skin were strikingly similar to those seen between skin of #1010 transgenic mice and controls.

EXAMPLE 5.

15

Scce-transgenic mice for testing of antipruritic agents

Transgenic mice, 18-22 weeks of age, mean weight 24.2 g, were given subcutaneous injections of either 250 µg of the glucocorticoid triamcinolone acetonide in a total volume of 100 µl on day 0, and 100 µg triamcinolone acetonide in a total volume of 100 µl on days 7, 14 and 21, or 100 µl of physiological saline at the same time points. Episodes of scratching were counted in the morning and injections were given in the afternoon. To prepare solutions for injections 25 µl or 10 µl of Kencort -T™ suspension, 10 mg/ml (Bristol-Myers Squibb), was mixed with 75 µl or 90 µl of physiological saline. The results are shown in Fig. 7. Triamcinolone acetonide was highly efficient in diminishing scratching.

Transgenic mice 20-21 weeks of age, mean weight 24.5 mg, were given either loratidine in a total volume of 100 µl, or 100 µl of a control solution by means of tube feeding. Episodes of scratching were counted immediately before feeding (0 hours), and then at time points as indicated. Feeding solutions were prepared by mixing either 30 µl of loratidine 1 mg/ml, sucrose 600 mg/ml (Clarityn mixture™, Schering-Plough), or, for control solutions, 30 µl of sucrose 600 mg/ml, with 70 µl of physiological saline. The results are shown in Figure 8A. The same mice were then treated 7 days later with 90 µl of loratidine mixture of sucrose solution mixed with 10 µl of physiological saline. The results are shown in Figure 8B. As seen from figures 8A and 8B there was no significant difference in frequency of scratching between treatment group and control group. This indicates that the itching behavior of the SCCE mouse is not relieved by treatment with an antihistamine.

The two experiments show that scce-transgenic mice can be used for evaluation of drugs with potential effects on itch (anti-pruritic drugs). The glucocorticoid triamcinolone acetonide appeared to be highly effective in relieving itch, whereas the antihistamine loratidine had no statistically significant antipruritic effect.

5

It thus appears that the pruritus in SCCE-transgenic mice respond to treatment with a glucocorticoid but not to treatment with an antihistamine. A similar situation can be found for human patients suffering from pruritus associated with e.g. atopic dermatitis, eczema, and psoriasis.

10

EXAMPLE 6

Determination of nucleotide sequences of homologues to hscce-cDNA from cow, rat and pig.

15

Skin biopsies from cow, pig and rat were obtained, immediately frozen in liquid nitrogen and homogenized, using a Mikro-Dismembrator U (B.Braun Biotech International GmbH, Melsungen, Germany) at 2000 rpm for 45 s. RNA was isolated using 1ml of Trizol Reagent (Life Technologies AB, Täby, Sweden) according to the manufacturers instructions, DNase treated, extracted with Phenol:CHCl₃, and precipitated with LiCl according to the Boehringer Mannheim protocol (Nonradioactive In Situ Hybridization application Manual, Boehringer Mannheim, Mannheim, Germany).

20

RT-PCR was performed as described (Lindström *et al.* with oligo d(T)₁₆ primers (Perkin Elmer, Foster City, CA, USA) in the RT reaction. In each RT reaction 100 ng of total RNA was used.

25

For PCR five primers were designed from conserved sequences found in hscce and mscce cDNA resulting in primers mS3, 698,696,H2 and mS4 (Table 4). PCR products were cloned into pCR II vector using the TOPO TA cloning kit (Invitrogen/NOVEX, Groenigen, The Netherlands) as recommended by the manufacturers. Plasmid DNA was isolated using the QIAprep Spin Miniprep Kit (Qiagen, Chatsworth, CA). Nucleotide sequencing was performed using the DYEnamic ET Terminator Cycle Sequencing Kit (Amersham Pharmacia Biotech Sverige, Uppsala, Sweden) and an ABI377 automated DNA sequencer (Perkin-Elmer).

35

To obtain the 5' cDNA end the SMART Race cDNA Amplification Kit (Clontech Laboratories, Inc., Palo Alto, Ca) was used according to the manufacturers instructions. Species specific primers were designed from the cDNA sequences obtained in previous steps (Table 4).

Table 4. Oligomer primers used in RT-PCR, 5'-RACE and nested 5'-RACE

Oligomers a – e were designed from conserved sequences found when comparing SCCE and mSCCE cDNA sequences. Positions are derived from the mSCCE cDNA (Bäckman et al.,

- 5 Oligomers f – j were designed based on nucleotide sequencing data from the preceding species specific cloning reactions.

Oligomer	Sequence, 5' to 3'	
a) mS3	CAAGGAGAAAGGATTATAGATGGCT	(SEQ ID NO: 31)
b) 698	AAGGCTCCGCACCCATGGCAG	(SEQ ID NO: 32)
10 c) 696	TGCAATGGTGACTCAGGGGGGCCCTT	(SEQ ID NO: 33)
d) H2	GACCCAGGCGTCTACACTCAAGT	(SEQ ID NO: 34)
e) mS4	GAGACCATGAAAACCCATCGCTAAC	(SEQ ID NO: 35)
f) KO0905	TGACTTTCTTCACACTGGACGACAGC	(SEQ ID NO: 36)
g) GR0905	CTTCACACTGGCTGATAGCCTGGCCG	(SEQ ID NO: 37)
15 h) Ngr	CAGGGTGGCGGAATGACCTCATGGCCCT	(SEQ ID NO: 38)
i) RÅ1016	CTACTCCACAAGGACCCATGTCAATGAC	(SEQ ID NO: 39)
j) nRÅ1016	GCTGTGTGCTGGCATTCCCGACTCTAAG	(SEQ ID NO: 40)

First strand cDNA was prepared from total RNA using SMART II oligonucleotide

- 20 (5'-AAGCAGTGGTAACAACGCAGAGTACGCGGG-3') (SEQ ID NO: 41) and 5'-RACE cDNA synthesis primer (5'-(T)₂₅N₁N-3') (N = A, C, G, or T; N₁ = A, G, or C) (SEQ ID NO: 42). 5'-RACE was performed using Universal primer mix (UPM) containing Long (0.02μM) (5'-CTAATACGACTCACTATAGGGCAAGCAGTGGTAACAACGCAGAGT-3') (SEQ ID NO: 43) and Short (1μM) (5'-CTAATACGACTCACTATAGGGCC-3') (SEQ ID NO: 44) universal primer
- 25 and a specific primer for each species (KO 0905, GR 0905 and RÅ 1016). Cyclic parameters for the PCR reaction were adapted from the manufacturers recommendations for a Perkin-Elmer DNA Thermal Cycler 480 but with 25 cycles in the last step. 5'-RACE PCR products from reactions with specific primers for pig and rat were subjected to nested PCR using Nested Universal Primer (NUP) (5'-AAGCAGTGGTAACAACGCAGAGT-3') (SEQ
- 30 ID NO: 45) and nested specific primers for pig (nGR0905) and rat (nRÅ1016) respectively. The nested PCR reactions were performed according to the manufacturers instructions with 20 cycles of amplification. Products from 5'-RACE and nested 5'-RACE were checked on agarose gel. For characterization products were cloned and sequenced as described above. The results are shown in table 5 as deduced amino acid sequences. Table 6 show the
- 35 calculated similarities of the active enzyme starting with the sequence IIDG. Sequences for human (Hansson et al., 1994) and mouse SCCE (Bäckman et al., 1999) are included for comparison.

The rat SCCE sequence shown in table 5 and in SEQ ID NO: 49 can not be found in the GenBank database which indicate that it does not correspond to any of the already known rat kallikreins or kallikrein like proteins.

- 5 Table 5. Alignment of the deduced amino acid sequences of SCCE from five species. The sequences for cow, pig, and rat are not complete in the C-terminal parts.

	seq2	----MTTPLVILLTTFALGSVA	QEDQGNKSGEKI	IDGVPCPRGSQ	PWQVALLKGSQ	LHCG	56
	seq3	MARPLLPPRLILLLSLALGSAA	QEGQ-DKSGEKI	IDGVPCPGGSR	PWQVALLKGNQ	LHCG	59
	seq1	MARSLLLPLQILLLSLALETAG	EEAQ----	GDKIIDGAPCARG	SHPWQVALLSGN	QLHCG	56
	seq4	-MGVWLLSLLTVLLSLALETAG	Q-----	GERIIDGYKCKEG	SHPWQVALLKGD	QLHCG	52
10	seq5	-MGVWLLSLITVLLSLALETAG	Q-----	GERIIDGIKCKEG	SHPWQVALLKGN	QLHCG	52
	seq2	GVLLEQWVLTAAHCMN-EYNVHMGS	VRLVGG--QKIKATRS	FRHPGYSTQTHAN	DLMLV	112	
	seq3	GVLVNQQWVLTAAHCMMNDYNVHLG	SDRLDDRKGQKIRAMRS	FRHPGYSTQTHVN	DLMLV	119	
	seq1	GVLVNERWVLTAAHCKMNEYTVHLG	SDTLGDRRAQRIKASKS	FRHPGYSTQTHVN	DLMLV	116	
	seq4	GVLVGESWVLTAAHCKMGQYTVHLG	SDKIEDQSAQRIKASRS	FRHPGYSTRTHVN	DIMLV	112	
15	seq5	GVLVDKYWVLTAAHCKMGQYQVQLG	SDKIGDQSAQKIKATKS	FRHPGYSTKTHVN	DIMLV	112	
	seq2	KLNGRAKLSSSVKKNLPSHCDPPGTM	CTVSGWGTTTSPDVT	FPQGLMCTDVKL	ISPQDC	172	
	seq3	KLSRPARLSASVKKVNLPSRCEPPGTT	CTVSGWGTTTSPDVT	FPADLMCTDVKL	ISSQDC	179	
	seq1	KLNSQARLSSMVKKVRLPSRCEPPGTT	CTVSGWGTTTSPDVT	FPSDLMCVDVKL	ISPQDC	176	
	seq4	KMDKPVKMSDKVQKVKLPDHCEPPGTL	CTVSGWGTTTSPDVT	FPSDLMCSDVKL	ISSQEC	171	
20	seq5	RLDEPVKMSSKVEAVQLPEHCEPPGT	SCTVSGWGTTTSPDVT	FPSDLMCSDVKL	ISSREC	172	
	seq2	RKVYKDLLGDSMLCAGI	PNSRTNACNGDSGGPLMCKGTL	QGVVSWGSPCGQPND	PGVYT	232	
	seq3	KKVYKDLLGSSMLCAGI	PNSKTNACNGDSGGPLVCKGTL	QGLVSWGTFPCGQPND	PGVYT	239	
	seq1	TKVYKDLLENSMLCAGI	PDSKKNACNGDSGGPLVCRGTL	QGLVSWGTFPCGQPND	PGVYT	236	
	seq4	KKVYKDL LGKTMLCAGI	PDSKTNTCNGDSGGPLVCNDTL	QGLVSWGTYPCGQPN-----	225		
	seq5	KKVYKDLLGKTMLCAGI	PDSKTNTCNGDSGGPLVCNDTL	QGLASRGTYPCGQPND	PGVYT	232	
25	seq2	QVCKYVNWIK-----	242				
	seq3	QVCKYIDWIN-----	249				
	seq1	QVCKFTKWINDTMKKHR	253				
	seq4	-----					
	seq5	QVCKYKRWVMETMKTHR	249				

- 30 Seq 2 (cow) in the figure is SEQ ID NO:46, Seq 3 (pig) in the figure is SEQ ID NO:47, Seq 1 (homo) in the figure is SEQ ID NO:48, Seq 4 (rat) in the figure is SEQ ID NO:49 and Seq 5 (mouse) in the figure SEQ ID NO:50.

Table 6. Calculated similarities of the active enzymes.

species compared	calculated similarity *
Mouse-human	75%
Rat-human	77%
Pig-human	77%
Cow-human	76%
Rat-mouse	88%
Cow-mouse	69%
Pig-mouse	69%

*The comparisons of active enzymes are starting with the sequence IIDG etc.

5 REFERENCES

- Ausubel et al. (1992). Current protocols in Molecular Biology. John Wiley & Sons
- Brattsand, M. & Egelrud, T. Purification, molecular cloning, and expression of a human
 10 stratum corneum trypsin-like serine protease with possible function in desquamation. *J Biol Chem* 274, 30033-30040 (1999).
- Bäckman, A., Stranden, P., Brattsand, M., Hansson, L. & Egelrud, T. Molecular cloning and
 tissue expression of the murine analog to human stratum corneum chymotryptic enzyme. *J*
 15 *Invest Dermatol* 113, 152-155 (1999).
- Chavanas, S. et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause
 Netherton syndrome. *Nat Genet* 25, 141-142 (2000).
- 20 Diamandis, E.P., Yousef, G.M., Liu-Ying, L., Magklara, A. & Obiezu, C.V. The New Human
 Kallikrein Gene Family - Implications in Carcinogenesis. *Trends in Endocrinology and Metabolism* 11, 54-60 (2000).
- Ekholm, E. & Egelrud, T. Stratum corneum chymotryptic enzyme in psoriasis. *Arch*
 25 *Dermatol Res* 291, 195-200 (1999).
- Ekholm, E. & Egelrud, T. The expression of stratum corneum chymotryptic enzyme in
 human anagen hair follicles: further evidence for its involvement in desquamation-like
 processes. *Br J Dermatol* 139, 585-590 (1998).

- Ekholm, I.E., Brattsand, M. & Egelrud, T. Stratum corneum tryptic enzyme in normal epidermis: a missing link in the desquamation process? *J Invest Dermatol* 114, 56-63 (2000).
- 5
- Hansson, L. et al. Cloning, expression, and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. *J Biol Chem* 269, 19420-19426 (1994).
- 10 Hogan, B., Constanini, F. & Lazy, E. 1986 *In Manipulating the mouse embryo: A Laboratory Manual*. Cold Spring Harbor, NY, Cold Spring Laboratory Press. (Cold Spring Laboratory Press, Cold Spring HarborNew York, 1986).
- Hägermark, D., Rajka, G. & Berqvist, U. Experimental Itch in human skin elicited by rat mast cell chymase. *Acta Derm Venereol (Stockh)* 52, 125-128 (1972).
- 15 Hägermark, O. Studies on experimental itch induced by kallikrein and bradykinin. *Acta Derm Venereol (Stockh)* 54, 397-400 (1974).
- 20 Kroon, E., MacDonal, R. J. & Hammer, R. E. The transcriptional regulatory strategy of the rat tissue kallikrein gene family. *Genes and Function* 1, 309-310 (1997).
- Lindström P., Bergh A., Holm I., Damber J. E. Expression of transforming growth factor-beta 1 in rat ventral prostate and Dunning R3327 PAP prostate tumor after castration and estrogen treatment. *Prostate* 29, 209-218 (1996).
- 25 Lusky, M. and Botchan M. Inhibition of sv40 replication in simian cells by specific pBR322 DNA sequences. *Nature*, 293, 79-81 (1981)
- 30 Sambrook et al. (1989) *Molecular Cloning: A laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. USA
- Sondell, B., Thornell, L.E. & Egelrud, T. Evidence that stratum corneum chymotryptic enzyme is transported to the stratum corneum extracellular space via lamellar bodies. *J Invest Dermatol* 104, 819-823 (1995).
- 35

Sondell, B., Dyberg, P., Anneroth, G.K., Ostman, P.O. & Egelrud, T. Association between expression of stratum corneum chymotryptic enzyme and pathological keratinization in human oral mucosa. *Acta Derm Venereol (Stockh)* 76, 177-181 (1996).

- 5 Vassar et al (1989) Tissue-specific and differentiation-specific expression of a human K14 keratin gene in transgenic mice. *Proc Natl Acad Sci U S A*.86, 1563-7.

PCT CLAIMS

1. A non-human transgenic mammal or mammalian embryo having integrated within its genome a heterologous nucleotide sequence comprising at least a significant part of a
5 nucleotide sequence coding for a stratum corneum chymotryptic enzyme (SCCE) or a variant thereof operably linked to a promoter that drives expression of said heterologous scce or a variant thereof in skin.
2. A non-human transgenic mammal or mammalian embryo according to claim 1 having
10 integrated within its genome a heterologous nucleotide sequence comprising at least a significant part of a nucleotide sequence coding for a protein with an amino acid sequence which has a sequence identity of at least 75% to the amino acid sequence shown in SEQ ID NO:2 and which contains the partial sequence glycine-X₁-X₂- isoleucine-isoleucine-aspartate-glycine, wherein X₁ is aspartate or glutamate and X₂ is lysine or arginine,
15 operably linked to a promoter that drives expression in skin.
3. A non-human transgenic mammal or mammalian embryo according to claim 1 or 2 having integrated within its genome a heterologous nucleotide sequence comprising at least a significant part of a nucleotide sequence coding for a protein with an amino acid
20 sequence which has a sequence identity of at least 75% to the amino acid sequence shown in SEQ ID NO:2 and which contains the partial sequence residue X₃-asparagine-X₄-X₅-X₆-X₇-X₈-serine, wherein X₃ is any amino acid residue, X₄ is any amino acid residue, X₅ is a cysteine residue, X₆ is any amino acid, X₇ is a glycine residue, X₈ is an aspartate residue, and the serine is the active serine residue characteristic of serine proteases, operably
25 linked to a promoter that drives expression in skin.
4. A non-human transgenic mammal or mammalian embryo according to any of claims 1-3 wherein said operably linked promoter drives expression of scce or a variant thereof in epidermis.
30
5. A non-human transgenic mammal or mammalian embryo according to any of claims 1-4 wherein the promoter is a ubiquitous promoter.
6. A non-human transgenic mammal or mammalian embryo according to any of claims 1-5
35 selected from the group consisting of rodents, cats and dogs.
7. A non-human transgenic mammal or mammalian embryo according to claim 6 which is a rodent selected from the group consisting of mice, rats and rabbits.

8. A non-human transgenic mammal or mammalian embryo according to claim 7 which is selected from the group consisting of mice.
- 5 9. A non-human transgenic mammal or mammalian embryo according to any of claims 1-8, wherein the nucleotide sequence comprises a significant part of a DNA sequence coding for human SCCE as shown in SEQ ID NO:1.
10. A non-human transgenic mammal or mammalian embryo according to any of claims 1-10 9, wherein the nucleotide sequence codes for a significant part of the peptide shown in SEQ ID NO. 2.
11. A non-human transgenic mammal or mammalian embryo according to claim 10, wherein the DNA sequence codes for the peptide corresponding to amino acid no. -7 15 through no. 224 of the amino acid sequence shown in SEQ ID NO. 2.
12. A non-human transgenic mammal or mammalian embryo according to claim 10, wherein the DNA sequence codes for the peptide corresponding to amino acid no. 1 through no. 224 of the amino acid sequence shown in SEQ ID NO. 2.
- 20 13. A non-human transgenic mammal or mammalian embryo according to any of claims 1-12, wherein the DNA sequence codes for the peptide shown in SEQ ID NO. 2.
14. A non-human transgenic mammal or mammalian embryo according to any of the 25 preceding claims, wherein the DNA sequence comprises the DNA shown in SEQ ID NO. 1.
15. A non-human transgenic mammal or mammalian embryo according any of the preceding claims, wherein the DNA sequence is SEQ ID NO:1.
- 30 16. A non-human transgenic mammal or mammalian embryo according to any of the preceding claims, wherein the promoter is a heterologous promoter.
17. A non-human transgenic mammal or mammalian embryo according to claim 16, wherein the promoter is an SV40 promoter.
- 35 18. A non-human transgenic mammal or mammalian embryo according to claim 17, wherein the promoter is the SV40 early promoter.

19. A non-human transgenic mammal or mammalian embryo according to any of the preceding claims, wherein the mammal exhibits an abnormal phenotype.
20. A non-human mammal or mammalian embryo according to claim 19, wherein the
5 mammal exhibits an abnormal skin phenotype.
21. A non-human mammal or mammalian embryo according to any of the preceding claims, wherein the mammal exhibits an abnormal phenotype or predisposition for cancer.
- 10 22. A non-human mammal or mammalian embryo according to claim 21, wherein the mammal exhibits a predisposition for ovarian cancer.
23. A non-human mammal or mammalian embryo according to claim 20, wherein the mammal exhibits an abnormal skin phenotype resembling a skin disease.
- 15 24. A non-human mammal or mammalian embryo according to claim 23, wherein the mammal exhibits epidermal hyperkeratosis, acanthosis, epidermal and/or dermal inflammation and/or pruritus.
- 20 25. A non-human mammal or mammalian embryo according to claim 23, wherein the mammal exhibits an abnormal skin phenotype resembling inflammatory skin diseases selected from the group of diseases consisting of epidermal hyperkeratosis, acanthosis, epidermal inflammation, dermal inflammation and pruritus.
- 25 26. A non-human mammal or mammalian embryo according to claim 23, wherein the mammal exhibits an abnormal skin phenotype resembling psoriasis.
27. A non-human mammal or mammalian embryo according to claim 23, wherein the mammal exhibits an abnormal skin phenotype resembling chronic atopic dermatitis or
30 chronic eczema.
28. A non-human mammal or mammalian embryo according to claim 23, wherein the mammal exhibits an abnormal skin phenotype resembling inherited skin diseases with epidermal hyperkeratosis.
- 35 29. A method for making a transgenic non-human mammal or mammalian embryo having integrated within its genome a heterologous nucleotide construct comprising at least a significant part of a nucleotide sequence coding for a stratum corneum chymotryptic

enzyme (SCCE) or a variant thereof operably linked to a promoter that drives expression of *scce* or a variant thereof in skin, the method comprising

(a) constructing and amplifying a nucleotide sequence comprising at least a significant part
5 of a nucleotide sequence coding for a stratum corneum chymotryptic enzyme (SCCE) or a variant thereof operably linked to a promoter that drives expression of *scce* or a variant thereof in skin,

(b) introducing into a non-human cell said heterologous nucleotide construct,

10

(c) using said cell or the progeny of said cell to create a number of putative transgenic non-human mammals or mammalian embryos,

(d) selecting said non-human mammal or mammalian embryo having said heterologous

15 nucleotide construct integrated within its genome.

30. A method for making a transgenic non-human mammal or mammalian embryo according to claim 29 wherein said operably linked promoter drives expression of *scce* or a variant thereof in epidermis.

20

31. A method for making a transgenic non human mammal according to claims 29 or 30, where the mammal exhibits an abnormal phenotype which is selected from the group of abnormal phenotypes consisting of predisposition for cancer, predisposition for ovarian cancer and a phenotype resembling a skin disease including a phenotype resembling
25 epidermal hyperkeratosis, acanthosis, epidermal inflammation, dermal inflammation, pruritus, psoriasis, chronic atopic dermatitis or chronic eczema.

32. A method according to any of claims 29-31 comprising introducing the SCCE-construct into an ovum or embryo of the mammal.

30

33. A method according to any of claims 29-32 comprising microinjecting the SCCE-construct into embryonal stem cells of the mammal.

34. A method according to any of claims 29-33 comprising microinjecting the SCCE-
35 construct into C57BL/6JxCBA-f2 mice ovum or embryos.

35. A method according to any of claims 29-34 comprising introduction of the SCCE-construct into C57BL/6JxCBA-f2 mice ova or embryos and breeding the resulting mice with C57BL/6JxCBA or with C57BL/6J to obtain transgenic progeny and stable mouse lines.

36. The use of the transgenic mammal or mammalian embryo according to any of claim 1-28 as a model for the study of disease with the aim of improving treatment, relieve or ameliorate a pathogenic condition, for development or testing of a cosmetic or a pharmaceutical formulation or for the development of a diagnostic method.
- 5
37. The use according to claim 36 of said transgenic mammal or mammalian embryo as a model for a skin disease.
38. The use according to claim 36 of said transgenic mammal or mammalian embryo as a
- 10 model for cancer.
39. The use according to claim 38 of said transgenic mammal or mammalian embryo as a model for skin cancer
- 15 40. A method of screening for a compound or composition effective for the prevention or treatment of an abnormal or unwanted phenotype, the method comprising
- (a) administering a compound or composition to a transgenic non-human mammal having integrated within its genome a nucleotide sequence coding for at least a significant part of
- 20 SCCE operably linked to a promoter that drives expression of the scce in an organ, wherein the rodent exhibits an abnormal phenotype,
- (b) evaluating the appearance of the relevant organ and/or the behaviour of a mammal treated according to step (a), and
- 25
- (c) comparing the appearance of the relevant organ and/or the behaviour of a treated rodent with an untreated control mammal.
41. A method according to claim 40 wherein the organ is the ovaries.
- 30
42. A method according to claim 40 wherein the organ is the skin.
43. A method according to claim 42 of screening for a compound or composition effective for the prevention or treatment of inflammatory skin diseases selected from the group of
- 35 diseases consisting of epidermal hyperkeratosis, acanthosis, epidermal inflammation, dermal inflammation and pruritus.
44. A method according to claim 42 of screening for a compound or composition effective for the prevention or treatment of atopic dermatitis or eczema.

45. A method according to claim 42 of screening for a compound or composition effective for the prevention or treatment of acne.
- 5 46. A method according to claim 42 of screening for a compound or composition effective for the prevention or treatment of inherited skin diseases with epidermal hyperkeratosis.
47. A method according to claim 40 of screening for a cosmetic composition.
- 10 48. A method of identifying a compound or composition effective for the prevention or treatment of an abnormal or unwanted phenotype, the method comprising
- (a) administering a compound or composition to a transgenic mammal having integrated within its genome a nucleotide sequence coding for at least a significant part of SCCE
- 15 operably linked to a promoter that drives expression of the scce in an organ, wherein the rodent exhibits an abnormal phenotype,
- (b) evaluating the appearance of the relevant organ and/or the behaviour of a mammal treated according to step (a), and
- 20 (c) comparing the appearance of the relevant organ and/or the behaviour of a treated rodent with an untreated control mammal.
- (d) Identifying the compound or composition as being effective for the prevention or
- 25 treatment of the abnormal or unwanted phenotype.
49. A method according to claim 48 wherein the organ is the ovaries.
50. A method according to claim 48 wherein the organ is the skin.
- 30 51. A method according to claim 50 of identifying a compound or composition effective for the prevention or treatment of inflammatory skin diseases selected from the group of diseases consisting of by epidermal hyperkeratosis, acanthosis, epidermal inflammation, dermal inflammation and pruritus.
- 35 52. A method according to claim 50 of identifying a compound or composition effective for the prevention or treatment of atopic dermatitis or eczema.

53. A method according to claim 50 of Identifying a compound or composition effective for the prevention or treatment of acne.

54. A method according to claim 50 of Identifying a compound or composition effective for
5 the prevention or treatment of inherited skin diseases with epidermal hyperkeratosis.

55. A method according to claim 48 of identifying a cosmetic composition.




Fig. 1




Fig. 2




Fig. 3A




Fig. 3B




Fig. 4A

Fig. 4B




Fig. 5A




Fig. 5B

A



Fig. 6A

B



Fig. 6B

C



Fig. 6C

D



Fig. 6D

E



Fig. 6E

F



Fig. 6F




Fig. 7




Fig. 8A




Fig. 8B

SEQUENCE LISTING

<110> Egelrud, Torbjorn
Hansson, Lennart

<120> SCCE modified transgenic mammals and
their use as models of human diseases

<130> P26024PC01

<150> PA 2001 00218

<151> 2001-02-09

<150> CA 2,332,655

<151> 2001-02-09

<160> 50

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 986

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (25)...(786)

<400> 1

```

gaattccgcg gatttccggg ctccatggca agatcccttc tcctgccct gcagatccta 60
                               Met Ala Arg Ser Leu Leu Leu Pro Leu
                               1                               5

ctgctatcct tagccttgga aactgcagga gaagaagccc agggtgacaa gattattgat 120
Gln Ile Leu Leu Leu Ser Leu Ala Leu Glu Thr Ala Gly Glu Glu Ala
 10                      15                      20                      25

ggcgccccat gtgcaagagg ctcccaccca tggcaggtgg ccctgctcag tggcaatcag 180
Gln Gly Asp Lys Ile Ile Asp Gly Ala Pro Cys Ala Arg Gly Ser His
                      30                      35                      40

ctccactgcg gaggcgtcct ggtcaatgag cgctgggtgc tcaactgccg ccaactgcaag 240
Pro Trp Gln Val Ala Leu Leu Ser Gly Asn Gln Leu His Cys Gly Gly
                      45                      50                      55

atgaatgagt acaccgtgca cctgggcagt gatacgctgg gcgacaggag agctcagagg 300
Val Leu Val Asn Glu Arg Trp Val Leu Thr Ala Ala His Cys Lys Met
                      60                      65                      70

atcaaggcct cgaagtcatt ccgccacccc ggctactcca cacagaccca tggttaatgac 360
Asn Glu Tyr Thr Val His Leu Gly Ser Asp Thr Leu Gly Asp Arg Arg
                      75                      80                      85

ctcatgctcg tgaagctcaa tagccaggcc aggctgtcat ccatggtgaa gaaagtcagg 420
Ala Gln Arg Ile Lys Ala Ser Lys Ser Phe Arg His Pro Gly Tyr Ser
 90                      95                      100                      105

```

2/18

ctgccctccc gctgcgaacc cccctggaacc acctgtactg tctccggctg gggcactacc 480
 Thr Gln Thr His Val Asn Asp Leu Met Leu Val Lys Leu Asn Ser Gln
 110 115 120

acgagcccag atgtgacctt tccctctgac ctcatgtgcg tggatgtcaa gctcatctcc 540
 Ala Arg Leu Ser Ser Met Val Lys Lys Val Arg Leu Pro Ser Arg Cys
 125 130 135

ccccaggact gcacgaaggt ttacaaggac ttactggaaa attccatgct gtgcgctggc 600
 Glu Pro Pro Gly Thr Thr Cys Thr Val Ser Gly Trp Gly Thr Thr Thr
 140 145 150

atccccgact ccaagaaaaa cgcttgcaat ggtgactcag ggggaccgtt ggtgtgcaga 660
 Ser Pro Asp Val Thr Phe Pro Ser Asp Leu Met Cys Val Asp Val Lys
 155 160 165

ggtaccctgc aaggtctggt gtcctgggga actttccctt gcggccaacc caatgaccca 720
 Leu Ile Ser Pro Gln Asp Cys Thr Lys Val Tyr Lys Asp Leu Leu Glu
 170 175 180 185

ggagtctaca ctcaagtgtg caagttcacc aagtggataa atgacaccat gaaaaagcat 780
 Asn Ser Met Leu Cys Ala Gly Ile Pro Asp Ser Lys Lys Asn Ala Cys
 190 195 200

cgctaacgcc aactgagtt aattaactgt gtgcttccaa cagaaaatgc acaggagtga 840
 Asn Gly Asp Ser Gly Gly Pro Leu Val Cys Arg Gly Thr Leu Gln Gly
 205 210 215

ggacgccgat gacctatgaa gtcaaatttg actttacctt tcctcaaaga tatatttaaa 900
 Leu Val Ser Trp Gly Thr Phe Pro Cys Gly Gln Pro Asn Asp Pro Gly
 220 225 230

cctcatgccc tggtgataaa ccaatcaaat tggtaaagac ctaaaaccaa aacaaataaa 960
 Val Tyr Thr Gln Val Cys Lys Phe Thr Lys Trp Ile Asn Asp Thr Met
 235 240 245

gaaacacaaa accctcaacg gaattc 986
 Lys Lys His Arg *
 250

<210> 2

<211> 253

<212> PRT

<213> Homo sapiens

<400> 2

Met Ala Arg Ser Leu Leu Leu Pro Leu Gln Ile Leu Leu Leu Ser Leu
 1 5 10 15
 Ala Leu Glu Thr Ala Gly Glu Glu Ala Gln Gly Asp Lys Ile Ile Asp
 20 25 30
 Gly Ala Pro Cys Ala Arg Gly Ser His Pro Trp Gln Val Ala Leu Leu
 35 40 45
 Ser Gly Asn Gln Leu His Cys Gly Gly Val Leu Val Asn Glu Arg Trp
 50 55 60
 Val Leu Thr Ala Ala His Cys Lys Met Asn Glu Tyr Thr Val His Leu
 65 70 75 80
 Gly Ser Asp Thr Leu Gly Asp Arg Arg Ala Gln Arg Ile Lys Ala Ser
 85 90 95
 Lys Ser Phe Arg His Pro Gly Tyr Ser Thr Gln Thr His Val Asn Asp
 100 105 110

3/18

Leu	Met	Leu	Val	Lys	Leu	Asn	Ser	Gln	Ala	Arg	Leu	Ser	Ser	Met	Val
	115						120					125			
Lys	Lys	Val	Arg	Leu	Pro	Ser	Arg	Cys	Glu	Pro	Pro	Gly	Thr	Thr	Cys
	130						135					140			
Thr	Val	Ser	Gly	Trp	Gly	Thr	Thr	Thr	Ser	Pro	Asp	Val	Thr	Phe	Pro
	145				150				155						160
Ser	Asp	Leu	Met	Cys	Val	Asp	Val	Lys	Leu	Ile	Ser	Pro	Gln	Asp	Cys
			165					170						175	
Thr	Lys	Val	Tyr	Lys	Asp	Leu	Leu	Glu	Asn	Ser	Met	Leu	Cys	Ala	Gly
			180					185					190		
Ile	Pro	Asp	Ser	Lys	Lys	Asn	Ala	Cys	Asn	Gly	Asp	Ser	Gly	Gly	Pro
	195					200					205				
Leu	Val	Cys	Arg	Gly	Thr	Leu	Gln	Gly	Leu	Val	Ser	Trp	Gly	Thr	Phe
	210					215					220				
Pro	Cys	Gly	Gln	Pro	Asn	Asp	Pro	Gly	Val	Tyr	Thr	Gln	Val	Cys	Lys
	225				230					235					240
Phe	Thr	Lys	Trp	Ile	Asn	Asp	Thr	Met	Lys	Lys	His	Arg			
			245					250							

<210> 3

<211> 9729

<212> DNA

<213> Homo sapiens

<400> 3

taccacattt	tcttaatcca	gtctatcact	gatggacatt	taggttgatt	ccctgtgttt	60
gctgttgtca	atagttctac	aatgaacgta	cgtgtccatg	tgtctttaa	cagaatgatt	120
tatattcctt	tgggtacaca	cactggggct	tatgagaggg	tggagagtgg	gaggaaggag	180
aggatcagaa	aaaaataact	aatgggtact	aggcttaata	cctgggtgat	taaataatct	240
gtataacaaa	cccccatggc	gcacgttcac	ctacgcaaca	aacctgcaca	tcctgcacat	300
gtacccccga	actgaaaagt	taaaaaaaga	aaaataaata	tttgcttata	aattaataaa	360
tgaagccctc	aaaaatgttc	tattagataa	tgtaagtac	agacattttt	gttataaata	420
cataatatac	aaagaaatct	atgtataaca	tgattaaaat	gaccataaga	acatagatcc	480
taaacatggc	aaatattagt	ggggtgggg	tagggaaagc	gttggtttta	acttacacct	540
ctctgttaga	gttgggaatg	ggttcaggcg	taattacagg	cacgactggg	atcagcttgg	600
acaagtcccc	ccaggcgggc	cagaattagg	atgtagggtc	taggccaccc	ctgagagggg	660
gtgagggcaa	gaaaatggcc	ccagaagccg	ggcgcagtgg	ctcacgcctg	taatcccagc	720
actttgcggg	gccgaggcgg	gcacatcatg	aggtcaggag	atcgagacca	ttctggccaa	780
catagtga	cccgggtctc	actaaaaata	caaaaattat	ctgggagtgg	tggtgcgtgc	840
ctgtataccc	aggctactcg	gaggctgagg	caggagaatc	acttgaacct	gggaggcgga	900
gctggcagtg	agccgagatc	gcgccaccgc	actccagcct	ggcgatagag	agagactcca	960
tccaaaaaaa	agaaaggaag	ggaggggagg	aggaggggaag	aaagaaagaa	aaccgccccca	1020
gagaaggacc	cgagccagag	cctattctct	gagctcagcg	actgcttgaa	ttccgctcct	1080
gcccctcaga	cccagcgcac	cgggtccctc	ccccgagagc	agccaggagg	gactgtggga	1140
ccagaatgtg	cgggggcgca	ggagctgggc	accgcccgtc	cttcggaggg	agggtggaga	1200
gagagtgcag	tggtgccaat	tgctctcgct	gcgtcagggt	tccagataac	cagaaccgca	1260
aatgcaggcg	ggggtgtccc	agagtgggct	ccgctgcac	cccagggcgc	tggggccggg	1320
catggggcgg	ggggtgat	aagaggacgg	cccagcagag	ggctgaagat	tttgagagccc	1380
agctgtgtgc	cagcccaagt	cgaacttg	atcacatcag	atcctctcga	ggtgagaaga	1440
ggcttcatca	agggtgcacc	tgtaggggag	ggggtgatgc	tggctccaag	cctgactctg	1500
ctctcgagag	gtaggggctg	cagcctagac	tcccggctcct	gagcagttag	ggcctggaag	1560
tctgcaattt	ggggcctttt	agggaataac	gaactacaga	gtcagaagtt	tgggttccac	1620
agggaagggc	aagatcggag	cctagattcc	tgggtctcta	gggatctgaa	gaacaggaat	1680
tttgggtctg	agggaggagg	ggctgggggt	ctggactcct	gggtctgagg	gaggagggcc	1740
tgggggcctg	gactcctggg	tctgaggggag	gaggggctgg	gggtctcgac	tcctgggtct	1800
gagggaggag	gggctggggg	cctggactcc	tgggtctgag	ggaggagggg	ctgggacctg	1860
gactcctagg	tctgaggggag	gaggagctgg	ggcctggact	cctgggtctg	agggaggagg	1920
ggctggggcc	tggactcctg	ggtctgaggg	aggatgggct	gaggccataga	ctcctgggtc	1980
tgaggggagga	ggggctgggg	cctggactcc	tgggtctgag	ggaggagggg	ctggagcctg	2040
gactcctggg	cctgaggggag	gagggactga	gacctggact	cctaggtctg	agggaggagg	2100

gactgggacc	tggactcctg	ggtctgaggg	aggaggagct	gggggcctgg	actcctgggt	2160
ctgagggagg	cggggctggg	ggcctggact	cctgggtctg	agggaggagg	ggttggggcc	2220
tggactcctg	agcctgaggg	aggagggact	tggacctgga	ctcctaggtc	tgagggagga	2280
ggagctgggg	gcctggactc	ctaggtctga	gggaggaggg	gctggggggc	tggactcctg	2340
ggtctgaggg	aggaaggtgc	tagggctctg	actcttgggt	atgaggagg	aggaggttag	2400
gggtctggac	ttctgagtg	aaggaaggag	aggccagaga	aaggaatttc	tgggtctgag	2460
ggaggagggg	ctgggggtct	ggaccctag	gtctgaggga	ggaggggctg	gggcctggac	2520
tcctgggtct	gtggggggag	gggtctgggc	ctggacccct	gggtctgagt	ggggaggggc	2580
tgggcctgaa	tgctttctcc	ttctcagctc	cagcaggaga	ggcccttcc	cgctctggcag	2640
cccctgagcg	gctcagcagg	gcaccatggc	aagatccctt	ctcctgcccc	tgagatcct	2700
actgctatcc	ttagccttgg	aaactgcagg	agaagaaggt	gaaagctgga	ctgggaagtc	2760
tgacctcacc	tcagggcccc	cactgacctt	ctccaaggag	tccttgagtc	agaaccttcc	2820
cctcctcaaa	cagcttccat	cctgggagga	cgactgtc	ggctgaagcc	ccgctcttc	2880
ctgcttctgc	tgactcaggg	ggtctctgtc	ccctccaggc	cctgcctcct	gtgctcaggg	2940
tctctctgtg	gttccccaga	tgagatgcgc	ctcctgggtt	tctgagtggg	ctccttctgt	3000
ctgtctctat	ccctatctct	tgctttctct	gtatttctcc	acacattttc	atctgtctct	3060
gtccatctct	gactctggga	atccctgagg	tgagcctca	gccttcccc	aatgctagct	3120
accacatctg	tcctccatgt	ctccatccag	cccagggtga	caagattatt	gatggcgccc	3180
catgtgcaag	aggctcccac	ccatggcagg	tggccctgct	cagtggcaat	cagctccact	3240
gcggaggcgt	cctggtcaat	gagcgtctgg	tgctcactgc	cgccactgc	aagatgaagt	3300
aggtgccacc	caagtctctg	ctggaggtgc	gccagcatct	ccagctcgct	atgggggtgg	3360
aagggcagtc	tttctgtgcc	tacggctcta	ttctcctctc	tctgggtctc	tgtccccctc	3420
tctctgggcc	tctgtacccc	ctctccctgg	ggctctgtcc	ccctctctcc	ctggctctct	3480
gtctccctct	ctctgggtct	ctgtccccct	ctctctggat	ctctgttccc	ctctctctgt	3540
gtctctgtcc	ccattctct	ctaggtctct	gttccccctc	ctctctctct	gggtctctgt	3600
ccctctctct	ctgggtctct	tccccctctc	tctctggatc	tctgtcccc	tctccctggg	3660
cctctgtacc	ccctctccct	ggggctctgt	ccccctctc	tgggtctctg	tctgcctttc	3720
tctctggatc	tctgttcccc	tctgtgtctc	tgtccccctc	tctctctggg	tctctgttcc	3780
ccctctctct	tttctgggtc	tctgtccctc	tctctctggg	tctctgtccc	cctctctctc	3840
tggtctctgt	tccccctct	ctctctctgg	tctctgtccc	tctctctctg	ggtctctgtc	3900
accctctctc	tctgggtctc	tgtaccctc	tctctctggg	ctctgttccc	cctcctctct	3960
ctgtgggtct	ctgtccctct	ctctctgggt	ctctgttccc	ctctctctct	ggtctctgtt	4020
ccccctcctc	tctctcogga	tctctgtccc	cctctccctg	gggtctctgt	ccccctctc	4080
cctggctctc	tgtcttccct	tctctggggc	tctgtcccc	tctctctctg	gtctctgttc	4140
ccctctctct	gggtctctgt	ccctctctct	ctgggtctct	gtccctctct	ctctggatct	4200
ctgtccccct	ctccctgggc	ctctgtacct	cctctccctg	gggtctctgt	ccccctctc	4260
tgggtctctg	tctgcctttc	tctctggatc	tctgttcccc	tctgtgtctc	tgtccccctc	4320
tctctctggg	tctctgttcc	ccctctctc	tttctgggtc	tctgtccctc	tctctctggg	4380
tctctgtccc	cctctctctc	tgggtctctgt	tccccctct	ctctctctgg	tctctgtccc	4440
tctctctctg	ggtctctgtc	accctctctc	tctgggtctc	tgtcaccctc	tctctctggt	4500
ctctgttccc	cctcctctct	ctgtgggtct	ctgtccctct	ctctctgggt	ctctgttccc	4560
ctctctctct	ggtctctgtt	ccccctcctc	tctctcogga	tctctgtccc	cctctccctg	4620
gggtctctgt	ccccctctc	cctgggtctc	tgtcttccct	tctctggggc	tctgtcccc	4680
tctctctctg	gtctctgttc	ccctctctct	gggtctctgt	ccctctctct	ctgggtctct	4740
gtccctctct	ctctggatct	ctgtccccct	ctctctctgg	gtctctgttc	ccctctctct	4800
gggtctctgt	ccccctctct	ctctctgtgt	ctctctcccc	ctcctctctc	tgtgtctctg	4860
tccccctctg	tatctctgtg	tctctctccc	ccctcctctc	tctgggtctc	tgtccccccc	4920
tctctgggtc	tctgtctccc	tctctctggg	gctctgtccc	cctctctctc	tggatctctg	4980
ttccccctct	tctgggtctc	tgtctccctc	cctctctctg	tgtctctgtc	ccccctcctc	5040
tctctgggtc	tctgtcccca	ccccgtcccc	caggtctttg	cacaccctct	ctgtcacagt	5100
gtctcttctg	aatctgtgaa	tgtcactcct	cgcagtgagt	acaccgtgca	cctgggcagt	5160
gatacgtctg	gcgacaggag	agctcagagg	atcaaggcct	cgaagtcat	ccgccacccc	5220
ggctactcca	cacagaccca	tgtaaatgac	ctcatgctcg	tgaagctcaa	tagccaggcc	5280
aggctgtcat	ccatggtgaa	gaaagtcaag	ctgccctccc	gctgcgaacc	ccctgggaacc	5340
acctgtactg	tctccggctg	gggcactacc	acgagcccag	atggtaggtg	gcctcagtga	5400
cccaggagtg	caggccccag	ccctcctccc	tcagacccag	gagtcaggcc	ccccagcccc	5460
tcctccctca	gacccaggag	tccaggcctc	agccctcctc	ccctcagacc	caggagtcca	5520
ggcccccagc	ccctcctccc	tcagaccgcg	gagtcagagc	cccagcccct	cctccctcag	5580
accagcagt	cctgggcccc	agaccctcct	ccctcggaac	caggagcctg	aacaacacag	5640
cttctgggtc	tcgcccccat	cctctctgac	tgacagctct	ccctgtcctc	ccctgcagtg	5700
acctttccct	ctgacctcat	gtgcgtggat	gtcaagctca	tctcccccca	ggactgcacg	5760

aaggtttaca	aggacttact	ggaaaattcc	atgctgtgcg	ctggcatccc	cgactccaag	5820
aaaaacgcct	gcaatgtgag	accctcccc	ccaattcctc	cccagtcctg	ggtaccctgt	5880
ctgcatgccc	caggacaga	gcttgaccca	agtgactggg	taccaagccc	ggccttgccc	5940
cccccccagg	cctggcctcc	tcagcttttt	ccacctcatt	ctctgcctag	gtcaggggtg	6000
ggagtttact	taggggccga	tgtggccctg	gggatgggac	agagagttta	ataggggtga	6060
gaaagtgggg	gtgggaccag	ggaaggagac	tgaggtgctg	gcctcaggcc	caaaccctaa	6120
gggggcacca	aaaacctcag	tgattgagat	aaatcataat	gcaatatatta	aaaaataaaa	6180
taaaaaactca	tgcagaagtc	catgatggac	aaaatgtcac	attttaataa	aagagcaggt	6240
ggatcttact	gaattttccc	ttgccgtaag	tactagcgtg	gctcagcaca	gcgctgtact	6300
ggcactgtct	tcattttaaaa	tgtggatacc	atgcccatac	tgcagtttta	tgtattacat	6360
ttgatttcgt	taagtactgc	attgaagtat	tgtgtattgc	agttactgag	attttgtgcc	6420
tgaagctgat	gactcactca	cctgaccctg	gccttggtcc	cggggaaaac	actctttctc	6480
tccacctcct	ctctgttccc	tctttctggc	cttttgtcat	ccctctgtt	tctgaacagt	6540
cttcccacat	ctctctttgt	gacataattt	catttcattc	ttttctctct	tgttttttct	6600
ctgtgttgag	ctagcttgct	ctccctccct	tgttctctct	ccatgccctc	ctctctgctc	6660
tctgtcttct	ccctctttct	cttgcctctc	tctctctcct	ccctccctc	tctctctctc	6720
ctgccccctt	gctctctctt	ttttctctct	tctctgtctc	ctctctggcc	ctctctctct	6780
tctctctctc	cccacttctc	ctgtctctct	tcctctctct	ccctcatctc	tccttgcccc	6840
ctccttttta	ctgtctctct	ctttctcttt	cttctatctc	tctctctctc	cgcgcgtctc	6900
cccctctctg	tctttctttc	tctctcttta	ttctctctct	ctcttccagt	ctctctctct	6960
tctccccacc	cccaccccat	ctctctcccc	acaccttccc	ccctttctct	tttgtctctc	7020
tcttctacct	ctttcttctc	cacccccatc	tctctctctc	ttctcttccc	acacctctcc	7080
catctccctc	atctctttgt	ctgtctctct	tctccctcct	tcttttccac	ccccatctct	7140
ctgtctctct	ctctccccat	accctttccc	tcttctcatc	ctctctttgt	ctctctctct	7200
tttccctctt	tcttctccac	ctccaaactc	ctctgtctct	ccacacccat	cctccttgct	7260
cacatctgca	ccttcagctg	tcaggggatg	tgggatggtg	agtgttaggg	atagaggaga	7320
tgggagagag	atgactgtcc	tagagaatag	ggtgttcccc	ttctcccctg	gtgagggcca	7380
gtttcatgaa	tgtgcaagct	ctgcacggac	acagagcccc	acactcagaa	gggtctcaaa	7440
cttagtctaa	tgcattcctg	ctgttgtctt	gaaattctca	ataatttttg	aacaaagggc	7500
cctgcatttt	cgttttgcac	caagtcctgt	aaattatgta	actggtcttc	accctggtct	7560
ccgagaccat	cgtgtccccc	tttctctgct	acagggcac	gcatccaccc	cttgagatg	7620
atgttccttc	tcccactagc	ttggagcagg	gtccttaaca	ttggaaaata	aagagtgtct	7680
tgatcctgga	agccccaccc	cttctctgca	attgggtctc	ttggccaagg	gtcaaaccag	7740
tgtcttcaaa	ggacctagtg	tgtccctagc	actagctctc	ccattagtcc	ccagagacaa	7800
tgagtctctt	ctcattggct	atggtggaag	tccataatct	gcaagacaaa	gaccgataac	7860
tgagggaatgt	atgagaatga	gttgggcttt	gatctgaagc	caaagttaat	ctccggtctc	7920
attccctcta	gggtgactca	gggggaccgt	tgggtgtgag	aggtaccctg	caaggtctgg	7980
tgtcctgggg	aactttccct	tgcggccaac	ccaatgaccc	aggagtctac	actcaagtgt	8040
gcaagttcac	caagtggata	aatgacacca	tgaaaaagca	tcgctaacgc	cacactgagt	8100
taattaactg	tgtgcttcca	acagaaaatg	cacaggagtg	aggacgccga	tgacctatga	8160
agtcaaaatt	gactttacct	ttcctcaaa	atatatttaa	acctcatgcc	ctgttgataa	8220
accaatcaaa	ttggtaaaga	cctaaaaaca	aaacaaataa	agaaacacaa	aacctcagt	8280
gctggagaag	agtcagttag	accagcactc	tcaaacactg	gaactggacg	ttcgtacagt	8340
ctttacggaa	gacacttggt	caacgtacac	cgagaccctt	attcaccacc	tttgacccag	8400
taactcta	cttaggaaga	acctactgaa	acaaaaaaaa	tccaaaatgt	agaacaagac	8460
ttgaatttac	catgatatta	tttatcacag	aaatgaagtg	aaaccatcaa	acatgttcca	8520
aaagtaccag	atggcttaaa	taatagtctg	gcttggcaca	acgatgtttt	ttttctttga	8580
gacagagtct	ctgttgcttg	ggctgcaatg	cagtgtatga	atcttggctc	actgcaacct	8640
ccgcctcctg	ggttcaagtg	attctcgtgc	ttcagcctcc	caagtaacctg	ggactacagg	8700
tgtgcaccac	cacaccaggc	taattttttg	tgtattttta	ctagagacag	ggtttcacca	8760
tgttggccag	cgtggctctg	aacgcctgac	ctcagatgat	ccaccacact	tggcctccca	8820
aagtgcctgg	attacaggca	tgagccacca	cggccagccc	acaatgat	tacaaacct	8880
ttaaaaatga	tacttagaca	gaattgtcag	tattattcaa	gaacatttag	gctataggat	8940
gttaaatgac	aaaaggaagg	acaaaaatat	atatgtatgt	gaccctaccc	ataaaaaatg	9000
aaatattcac	agaatcagat	ctgaaaacac	atgtcccaga	ctgcatactg	gggtcgtcat	9060
gaggtgtctc	cttccctctg	tgtacttttc	cttgaatgtg	cacttttata	acatgaaaaa	9120
taaaggtggg	gaaaaaagtc	tgaagatcta	agattggaga	gaggtgacct	ttcaggaagg	9180
gagactagaa	agaaatatgt	gcctggtttt	gagccctggg	cctgccggcc	ctgttccagg	9240
gcatatttcc	atttcccaga	tctcagtttt	tctgtctgt	aaaatgggag	agagaggaaa	9300
ggatggagag	aggaagaagg	aaggaggagg	ggaggagaga	acaggccaac	ttcatcagcg	9360
tgggaagggg	tgtgaaagtg	tttctgagca	tctcacgagt	gacaagttag	gagggaggct	9420

ggcgggttttc agaggggattg ggatgacagt agacaggaca caggggtccc acaggggtct 9480
gccagaagta agcaaacagt gccggaggaa gatggtggca cctgctcccc aagaaggag 9540
ggaaaggaac ctcgggaagc gggtaggatg agggaggagt cctctgtgac tcagagcctg 9600
gccacagccc cagccatcta acatcaaaga tcctctgtgt ggtcacacct cagacgctgc 9660
tgaccgagga gccactccag cccaggacac gccctcctac ctgtttcttc tgtttttctc 9720
ccagaattc 9729

<210> 4
<211> 23
<212> PRT
<213> Bos taurus

<400> 4
Ala Gly Ile Pro Asn Ser Arg Thr Asn Ala Cys Asn Gly Asp Ser Gly
1 5 10 15
Gly Pro Leu Met Cys Lys Gly
20

<210> 5
<211> 23
<212> PRT
<213> Sus scrofa

<400> 5
Ala Gly Ile Pro Asn Ser Lys Thr Asn Ala Cys Asn Gly Asp Ser Gly
1 5 10 15
Gly Pro Leu Val Cys Lys Gly
20

<210> 6
<211> 23
<212> PRT
<213> Homo sapiens

<400> 6
Ala Gly Ile Pro Asp Ser Lys Lys Asn Ala Cys Asn Gly Asp Ser Gly
1 5 10 15
Gly Pro Leu Val Cys Arg Gly
20

<210> 7
<211> 23
<212> PRT
<213> Rattus norvegicus

<400> 7
Ala Gly Ile Pro Asp Ser Lys Thr Asn Thr Cys Asn Gly Asp Ser Gly
1 5 10 15
Gly Pro Leu Val Cys Asn Asp
20

<210> 8
<211> 23
<212> PRT
<213> Mus musculus

<400> 8

7/18

Ala Gly Ile Pro Asp Ser Lys Thr Asn Thr Cys Asn Gly Asp Ser Gly
 1 5 10 15
 Gly Pro Leu Val Cys Asn Asp
 20

<210> 9
 <211> 38
 <212> PRT
 <213> Bos taurus

<400> 9
 Gln Glu Asp Gln Gly Asn Lys Ser Gly Glu Lys Ile Ile Asp Gly Val
 1 5 10 15
 Pro Cys Pro Arg Gly Ser Gln Pro Trp Gln Val Ala Leu Leu Lys Gly
 20 25 30
 Ser Gln Leu His Cys Gly
 35

<210> 10
 <211> 37
 <212> PRT
 <213> Sus scrofa

<400> 10
 Gln Glu Gly Gln Asp Lys Ser Gly Glu Lys Ile Ile Asp Gly Val Pro
 1 5 10 15
 Cys Pro Gly Gly Ser Arg Pro Trp Gln Val Ala Leu Leu Lys Gly Asn
 20 25 30
 Gln Leu His Cys Gly
 35

<210> 11
 <211> 34
 <212> PRT
 <213> Homo sapiens

<400> 11
 Glu Glu Ala Gln Gly Asp Lys Ile Ile Asp Gly Ala Pro Cys Ala Arg
 1 5 10 15
 Gly Ser His Pro Trp Gln Val Ala Leu Leu Ser Gly Asn Gln Leu His
 20 25 30
 Cys Gly

<210> 12
 <211> 31
 <212> PRT
 <213> Rattus norvegicus

<400> 12
 Gln Gly Glu Arg Ile Ile Asp Gly Tyr Lys Cys Lys Glu Gly Ser His
 1 5 10 15
 Pro Trp Gln Val Ala Leu Leu Lys Gly Asp Gln Leu His Cys Gly
 20 25 30

<210> 13

<211> 31
<212> PRT
<213> Mus musculus

<400> 13
Gln Gly Glu Arg Ile Ile Asp Gly Ile Lys Cys Lys Glu Gly Ser His
1 5 10 15
Pro Trp Gln Val Ala Leu Leu Lys Gly Asn Gln Leu His Cys Gly
20 25 30

<210> 14
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Consensus sequence for cleavage site in C-terminal
of SCCE.

<221> VARIANT
<222> 2
<223> Asp = either aspartate (Asp) or glutamate (Glu).

<221> VARIANT
<222> 3
<223> Lys = either lysine (Lys) or arginine (Arg).

<400> 14
Gly Asp Lys Ile Ile Asp Gly
1 5

<210> 15
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> consensus of the substrate specificity pouch.

<221> VARIANT
<222> 1
<223> Thr = any amino acid residue.

<221> VARIANT
<222> 3
<223> Ala = any amino acid residue.

<221> VARIANT
<222> 5
<223> Asn = any amino acid residue.

<400> 15
Thr Asn Ala Cys Asn Gly Asp Ser
1 5

<210> 16
<211> 20

<212> DNA
<213> Atificial sequence

<220>
<223> PCR primer SYM3300.

<400> 16
ggtggccctg ctcagtggca 20

<210> 17
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer SYM3301.

<400> 17
caccatggat gacacagcct gg 22

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer SYM3302.

<400> 18
aataaagaaa cacaaaaccc 20

<210> 19
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer SYM3418.

<400> 19
tgtaatatca ttgtgggc 18

<210> 20
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer SYM4118.

<400> 20
ggatgtgaag ctcacctc 18

<210> 21
<211> 18
<212> DNA
<213> Artificial Sequence

<220>

<223> PCR primer SYM4121.

<400> 21

tggagtcggg gatgccag

18

<210> 22

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer SYM4720.

<400> 22

gggagggtgg agagagagtg cagtg

25

<210> 23

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer SYM4899.

<400> 23

agtctaggct gcagccccta c

21

<210> 24

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer hEXON1.

<400> 24

ctcgagggat ctgatgtgat cc

22

<210> 25

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer mEXON1.

<400> 25

ctgggagtga cttggcgtgg ctct

24

<210> 26

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer specific for human SCCE IE2.

<400> 26

gctctcccat tagtccccag aga

23

<210> 27

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer specific for human SCCE MJ2.

<400> 27

ccacttggtg aacttgacac cttg

24

<210> 28

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> forward primer covering the position 427 - 444 of the human SCCE cDNA sequence.

<400> 28

gcgaaccccc tggaacaa

18

<210> 29

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> reverse primer covering the position 490 - 510 of the human cDNA sequence in exon five.

<400> 29

acatccacgc acatgaggtc a

21

<210> 30

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> The real time amplification probe covering the position 445 - 473 of the human cDNA sequence in exon four.

<400> 30

cctgtactgt ctccggctgg ggcaactacc

29

<210> 31

<211> 25

<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer mS3.

<400> 31
caaggagaaa ggattataga tggct

25

<210> 32
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer 698.

<400> 32
aaggctccgc acccatggca g

21

<210> 33
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer 696.

<400> 33
tgcaatggtg actcaggggg gccctt

26

<210> 34
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer H2.

<400> 34
gacccaggcg tctacactca agt

23

<210> 35
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer mS4.

<400> 35
gagaccatga aaacccatcg ctaac

25

<210> 36
<211> 26
<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer KO 0905.

<400> 36

tgactttctt cacactggac gacagc

26

<210> 37

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer GR 0905.

<400> 37

cttcacactg gctgatagcc tggccg

26

<210> 38

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer Ngr.

<400> 38

cagggtggcg gaatgacctc atggccct

28

<210> 39

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer RÅ 1016.

<400> 39

ctactccaca aggacccatg tcaatgac

28

<210> 40

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer nRÅ 1016.

<400> 40

gctgtgtgct ggcattcccg actctaag

28

<210> 41

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> SMART II oligonucleotide.

<400> 41

aagcagtggg aacaacgcag agtacgcggg

30

<210> 42

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> 5'-RACE cDNA synthesis primer.

<221> variation

<222> 27

<223> n = a or g or c or t

<400> 42

tttttttttt tttttttttt tttttvn

27

<210> 43

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Long universal primer.

<400> 43

ctaatacgac tcactatagg gcaagcagtg gtaacaacgc agagt

45

<210> 44

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Short universal primer.

<400> 44

ctaatacgac tcactatagg gcc

23

<210> 45

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Nested universal primer.

<400> 45

aagcagtggg aacaacgcag agt

23

<210> 46

<211> 243

<212> PRT

<213> Artificial Sequence

<220>

<223> Deduced amino acid sequence from the C-terminal part of SCCE from cow.

<400> 46

```

Met Thr Thr Pro Leu Val Ile Leu Leu Leu Thr Phe Ala Leu Gly Ser
 1          5          10          15
Val Ala Gln Glu Asp Gln Gly Asn Lys Ser Gly Glu Lys Ile Asp
 20          25          30
Gly Val Pro Cys Pro Arg Gly Ser Gln Pro Trp Gln Val Ala Leu Leu
 35          40          45
Lys Gly Ser Gln Leu His Cys Gly Gly Val Leu Leu Asn Glu Gln Trp
 50          55          60
Val Leu Thr Ala Ala His Cys Met Asn Glu Tyr Asn Val His Met Gly
 65          70          75          80
Ser Val Arg Leu Val Gly Gly Gln Lys Ile Lys Ala Thr Arg Ser Phe
 85          90          95
Arg His Pro Gly Tyr Ser Thr Gln Thr His Ala Asn Asp Leu Met Leu
100          105          110
Val Lys Leu Asn Gly Arg Ala Lys Leu Ser Ser Ser Val Lys Lys Val
115          120          125
Asn Leu Pro Ser His Cys Asp Pro Pro Gly Thr Met Cys Thr Val Ser
130          135          140
Gly Trp Gly Thr Thr Thr Ser Pro Asp Val Thr Phe Pro Gly Gln Leu
145          150          155          160
Met Cys Thr Asp Val Lys Leu Ile Ser Pro Gln Asp Cys Arg Lys Val
165          170          175
Tyr Lys Asp Leu Leu Gly Asp Ser Met Leu Cys Ala Gly Ile Pro Asn
180          185          190
Ser Arg Thr Asn Ala Cys Asn Gly Asp Ser Gly Gly Pro Leu Met Cys
195          200          205
Lys Gly Thr Leu Gln Gly Val Val Ser Trp Gly Ser Phe Pro Cys Gly
210          215          220
Gln Pro Asn Asp Pro Gly Val Tyr Thr Gln Val Cys Lys Tyr Val Asn
225          230          235          240
Trp Ile Lys

```

<210> 47

<211> 249

<212> PRT

<213> Artificial Sequence

<220>

<223> Deduced amino acid sequence from the C-terminal part of SCCE from pig.

<400> 47

```

Met Ala Arg Pro Leu Leu Pro Pro Arg Leu Ile Leu Leu Leu Ser Leu
 1          5          10          15
Ala Leu Gly Ser Ala Ala Gln Glu Gly Gln Asp Lys Ser Gly Glu Lys
 20          25          30
Ile Ile Asp Gly Val Pro Cys Pro Gly Gly Ser Arg Pro Trp Gln Val
 35          40          45
Ala Leu Leu Lys Gly Asn Gln Leu His Cys Gly Gly Val Leu Val Asn
 50          55          60
Gln Gln Trp Val Leu Thr Ala Ala His Cys Met Met Asn Asp Tyr Asn
 65          70          75          80
Val His Leu Gly Ser Asp Arg Leu Asp Asp Arg Lys Gly Gln Lys Ile
 85          90          95

```


16/18

```

Arg Ala Met Arg Ser Phe Arg His Pro Gly Tyr Ser Thr Gln Thr His
      100      105      110
Val Asn Asp Leu Met Leu Val Lys Leu Ser Arg Pro Ala Arg Leu Ser
      115      120      125
Ala Ser Val Lys Lys Val Asn Leu Pro Ser Arg Cys Glu Pro Pro Gly
      130      135      140
Thr Thr Cys Thr Val Ser Gly Trp Gly Thr Thr Thr Ser Pro Asp Val
      145      150      155      160
Thr Phe Pro Ala Asp Leu Met Cys Thr Asp Val Lys Leu Ile Ser Ser
      165      170      175
Gln Asp Cys Lys Lys Val Tyr Lys Asp Leu Leu Gly Ser Ser Met Leu
      180      185      190
Cys Ala Gly Ile Pro Asn Ser Lys Thr Asn Ala Cys Asn Gly Asp Ser
      195      200      205
Gly Gly Pro Leu Val Cys Lys Gly Thr Leu Gln Gly Leu Val Ser Trp
      210      215      220
Gly Thr Phe Pro Cys Gly Gln Pro Asn Asp Pro Gly Val Tyr Thr Gln
      225      230      235      240
Val Cys Lys Tyr Ile Asp Trp Ile Asn
      245

```

<210> 48

<211> 253

<212> PRT

<213> Artificial Sequence

<220>

<223> Deduced amino acid sequence from the C-terminal
part of SCCE from homo.

<400> 48

```

Met Ala Arg Ser Leu Leu Leu Pro Leu Gln Ile Leu Leu Leu Ser Leu
  1      5      10      15
Ala Leu Glu Thr Ala Gly Glu Glu Ala Gln Gly Asp Lys Ile Ile Asp
      20      25      30
Gly Ala Pro Cys Ala Arg Gly Ser His Pro Trp Gln Val Ala Leu Leu
      35      40      45
Ser Gly Asn Gln Leu His Cys Gly Gly Val Leu Val Asn Glu Arg Trp
      50      55      60
Val Leu Thr Ala Ala His Cys Lys Met Asn Glu Tyr Thr Val His Leu
      65      70      75      80
Gly Ser Asp Thr Leu Gly Asp Arg Arg Ala Gln Arg Ile Lys Ala Ser
      85      90      95
Lys Ser Phe Arg His Pro Gly Tyr Ser Thr Gln Thr His Val Asn Asp
      100      105      110
Leu Met Leu Val Lys Leu Asn Ser Gln Ala Arg Leu Ser Ser Met Val
      115      120      125
Lys Lys Val Arg Leu Pro Ser Arg Cys Glu Pro Pro Gly Thr Thr Cys
      130      135      140
Thr Val Ser Gly Trp Gly Thr Thr Thr Ser Pro Asp Val Thr Phe Pro
      145      150      155      160
Ser Asp Leu Met Cys Val Asp Val Lys Leu Ile Ser Pro Gln Asp Cys
      165      170      175
Thr Lys Val Tyr Lys Asp Leu Leu Glu Asn Ser Met Leu Cys Ala Gly
      180      185      190
Ile Pro Asp Ser Lys Lys Asn Ala Cys Asn Gly Asp Ser Gly Gly Pro
      195      200      205
Leu Val Cys Arg Gly Thr Leu Gln Gly Leu Val Ser Trp Gly Thr Phe
      210      215      220
Pro Cys Gly Gln Pro Asn Asp Pro Gly Val Tyr Thr Gln Val Cys Lys

```

225 230 235 240
Phe Thr Lys Trp Ile Asn Asp Thr Met Lys Lys His Arg
 245 250

```
<210> 49
<211> 226
<212> PRT
<213> Artificial Sequence
```

<220>
<223> Deduced amino acid sequence from the C-terminal
part of SCCE from rat.

<400>	49
Met Gly Val Trp Leu Leu Ser Leu Leu Thr Val Leu Leu Ser Leu Ala 1 5 10 15	
Leu Glu Thr Ala Gln Gly Glu Arg Ile Ile Asp Gly Tyr Lys Cys 20 25 30	
Lys Glu Gly Ser His Pro Trp Gln Val Ala Leu Leu Lys Gly Asp Gln 35 40 45	
Leu His Cys Gly Gly Val Leu Val Gly Glu Ser Trp Val Leu Thr Ala 50 55 60	
Ala His Cys Lys Met Gly Gln Tyr Thr Val His Leu Gly Ser Asp Lys 65 70 75 80	
Ile Glu Asp Gln Ser Ala Gln Arg Ile Lys Ala Ser Arg Ser Phe Arg 85 90 95	
His Pro Gly Tyr Ser Thr Arg Thr His Val Asn Asp Ile Met Leu Val 100 105 110	
Lys Met Asp Lys Pro Val Lys Met Ser Asp Lys Val Gln Lys Val Lys 115 120 125	
Leu Pro Asp His Cys Glu Pro Pro Gly Thr Leu Cys Thr Val Ser Gly 130 135 140	
Trp Gly Thr Thr Thr Ser Pro Asp Val Thr Phe Pro Ser Asp Leu Met 145 150 155 160	
Cys Ser Asp Val Lys Leu Ile Ser Ser Gln Glu Cys Lys Lys Val Tyr 165 170 175	
Lys Asp Leu Leu Gly Lys Thr Met Leu Cys Ala Gly Ile Pro Asp Ser 180 185 190	
Lys Thr Asn Thr Cys Asn Gly Asp Ser Gly Gly Pro Leu Val Cys Asn 195 200 205	
Asp Thr Leu Gln Gly Leu Val Ser Trp Gly Thr Tyr Pro Cys Gly Gln 210 215 220	
Pro Asn 225	

```
<210> 50
<211> 249
<212> PRT
<213> Artificial Sequence
```

<220>
<223> Deduced amino acid sequence from the C-terminal
part of SCCE from mouse.

```

<400> 50
Met Gly Val Trp Leu Leu Ser Leu Ile Thr Val Leu Leu Ser Leu Ala
 1          5          10          15
Leu Glu Thr Ala Gly Gln Gly Glu Arg Ile Ile Asp Gly Ile Lys Cys
      20          25          30

```

PCT/IB02/01300

Lys	Glu	Gly 35	Ser	His	Pro	Trp	Gln 40	Val	Ala	Leu	Leu	Lys 45	Gly	Asn	Gln
Leu	His 50	Cys	Gly	Gly	Val	Leu 55	Val	Asp	Lys.	Tyr	Trp 60	Val	Leu	Thr	Ala
Ala 65	His	Cys	Lys	Met	Gly 70	Gln	Tyr	Gln	Val	Gln 75	Leu	Gly	Ser	Asp	Lys 80
Ile	Gly	Asp	Gln	Ser 85	Ala	Gln	Lys	Ile	Lys 90	Ala	Thr	Lys	Ser	Phe 95	Arg
His	Pro	Gly	Tyr 100	Ser	Thr	Lys	Thr	His 105	Val	Asn	Asp	Ile	Met 110	Leu	Val
Arg	Leu	Asp 115	Glu	Pro	Val	Lys	Met 120	Ser	Ser	Lys	Val	Glu 125	Ala	Val	Gln
Leu	Pro	Glu	His	Cys	Glu	Pro 135	Pro	Gly	Thr	Ser	Cys 140	Thr	Val	Ser	Gly
Trp 145	Gly	Thr	Thr	Thr	Ser 150	Pro	Asp	Val	Thr	Phe 155	Pro	Ser	Asp	Leu	Met 160
Cys	Ser	Asp	Val	Lys 165	Leu	Ile	Ser	Ser	Arg 170	Glu	Cys	Lys	Lys	Val 175	Tyr
Lys	Asp	Leu	Leu 180	Gly	Lys	Thr	Met	Leu 185	Cys	Ala	Gly	Ile	Pro 190	Asp	Ser
Lys	Thr	Asn 195	Thr	Cys	Asn	Gly	Asp 200	Ser	Gly	Gly	Pro	Leu 205	Val	Cys	Asn
Asp	Thr 210	Leu	Gln	Gly	Leu	Ala 215	Ser	Arg	Gly	Thr	Tyr 220	Pro	Cys	Gly	Gln
Pro 225	Asn	Asp	Pro	Gly	Val 230	Tyr	Thr	Gln	Val	Cys 235	Lys	Tyr	Lys	Arg	Trp 240
Val	Met	Glu	Thr	Met 245	Lys	Thr	His	Arg							

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.